Details of the Researcher

PHOTO

Michihisa Umetsu
Section
Tohoku University Hospital
Job title
Senior Assistant Professor
Degree

  • 博士（医学）（東北大学）

e-Rad No.
00910647
Researcher ID
Q-2366-2018

Research History 7

  • 2025/04 - Present
    東北大学病院　総合地域医療教育支援部

  • 2021/04 - Present
    Tohoku Unversity Hospital　Disivion of Vascular Surgery, Department of Surgery

  • 2019/10 - 2021/03
    Kesennuma City Hospital

  • 2017/02 - 2019/09
    東北少年院　医務課　医務課長

  • 2014/04 - 2019/09
    Tohoku University Hospital

  • 2011/04 - 2014/03
    Ishinomaki Red Cross Hospital　Surgery

  • 2009/04 - 2011/03
    Ishinomaki Red Cross Hospital

Show all Show first 5

Education 2

  • Tohoku University　Graduate School of Medicine

    2014/04 - 2019/03

  • Yamagata University

    2003/04 - 2009/03

Committee Memberships 7

  • 宮城県医師育成機構　キャリアコーディネーター

    2025/04 - Present

  • 日本静脈学会　静脈疾患サーベイ委員会委員

    2024/06 - Present

  • 日本静脈学会　倫理委員会委員

    2023/11 - Present

  • 日本血管外科学会　外保連委員会委員

    2023/05 - Present

  • 宮城県医師育成機構　地域医療調整・広報委員会

    2023/04 - Present

  • 宮城県医師育成機構　地域医療医師養成委員会

    2023/04 - Present

  • 宮城県医師育成機構　臨床教育・研修体制整備委員会

    2023/04 - Present

Show all ︎Show first 5

Professional Memberships 7

  • THE JAPANESE SOCIETY OF GASTROENTEROLOGICAL SURGERY

  • JAPAN SURGICAL ASSOCIATION

  • JAPANESE SOCIETY OF PHLEBOLOGY

  • Japanese College of Angiology

  • THE JAPANESE SOCIETY FOR CARDIOVASCULAR SURGERY

  • JAPANESE SOCIETY FOR VASCULAR SURGERY

  • JAPAN SURGICAL SOCIETY

︎Show all ︎Show first 5

Research Interests 3

  • Venous thromboembolism

  • Peripheral artery disease

  • Aneurysm

Research Areas 3

  • Life sciences / Cardiology /

  • Life sciences / Cardiovascular surgery /

  • Life sciences / General surgery, pediatric surgery /

Papers 55

  1. D-dimer after 3 months of anticoagulation therapy and outcomes in cancer-associated isolated distal deep vein thrombosis Peer-reviewed

    Tatsuya Nishikawa, Yugo Yamashita, Masashi Fujita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Nobutaka Ikeda, Kazunori Otsui, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Ryuki Chatani, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Taku Yasui, Hironori Yamamoto, Koh Ono, Takeshi Kimura

    Blood Vessels, Thrombosis & Hemostasis　2025/05

    DOI： 10.1016/j.bvth.2025.100063 　

  2. Clinical outcomes of cancer-associated isolated distal deep vein thrombosis: a comparison between asymptomatic and symptomatic thrombosis-findings from the ONCO DVT Study. International-journal Peer-reviewed

    Yoshito Ogihara, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Tatsuya Nishikawa, Nobutaka Ikeda, Kazunori Otsui, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Ryuki Chatani, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Toru Sato, Takeshi Kimura, Kaoru Dohi

    Research and practice in thrombosis and haemostasis　9　(2)　102722-102722　2025/02

    DOI： 10.1016/j.rpth.2025.102722 　

    More details Close

    BACKGROUND: The risk of recurrent venous thromboembolism (VTE) in patients with isolated distal deep vein thrombosis (IDDVT) is generally low, particularly when IDDVT is asymptomatic. However, cancer patients with IDDVT, even asymptomatic IDDVT, may be at a higher risk of recurrent VTE. OBJECTIVES: To compare the clinical outcomes of cancer patients with asymptomatic and symptomatic IDDVT. METHODS: The ONCO DVT trial is a randomized clinical trial that compared 12-month versus 3-month edoxaban treatment regimens in cancer patients with IDDVT. In this post hoc analysis, 601 patients were categorized into the asymptomatic (n = 479) and symptomatic (n = 122) groups based on IDDVT-related symptoms at diagnosis. The primary outcome was the composite of symptomatic recurrent VTE or VTE-related death at 12 months, while the major secondary outcome was major bleeding at 12 months. RESULTS: The cumulative 12-month incidence of the primary outcome was lower in the asymptomatic group than that in the symptomatic group (2.9% vs 13.4%; P < .001; hazard ratio, 0.21; 95% CI, 0.10-0.47). Among the 12 patients with symptomatic recurrent VTE in the asymptomatic group, 8 (67%) had recurrent IDDVT, and 11 (92%) experienced recurrence after discontinuing anticoagulation therapy. The cumulative 12-month incidence of major bleeding was lower in the asymptomatic group than that in the symptomatic group (7.8% and 13.2%; P = .048). CONCLUSION: The risk of recurrent symptomatic VTE was lower in cancer patients with asymptomatic IDDVT than in those with symptomatic IDDVT. Most recurrent VTE events were recurrent IDDVT, with the majority occurring after discontinuing anticoagulation therapy.

  3. Improvement of Gait Biomechanics after Endovascular Therapy for Patients with Intermittent Claudication Associated with Aortoiliac Occlusive Disease. Peer-reviewed

    Norinobu Ogasawara, Takaaki Kakihana, Daijirou Akamatsu, Yuta Tajima, Michihisa Umetsu, Takanori Ishida, Michiaki Unno, Hitoshi Goto, Takashi Kamei, Masahiro Kohzuki

    Annals of vascular diseases　18　(1)　2025

    DOI： 10.3400/avd.oa.25-00006 　

    More details Close

    Objectives: Gait disturbances increase mortality rates in lower extremity artery disease. Changes in gait biomechanics after endovascular therapy for intermittent claudication associated with lower extremity artery disease remain unknown. This prospective study investigated the effect of endovascular therapy on gait biomechanics in intermittent claudication. Methods: We recruited 10 patients (14 affected limbs) with intermittent claudication caused by isolated aortoiliac artery lesions who underwent endovascular therapy, and 10 healthy controls. Using 3-dimensional motion analysis, we measured biomechanical gait parameters preoperatively and over 6 months postoperatively, comparing them with those of healthy controls. Results: One month after endovascular therapy, parameters improved significantly compared with preoperative values: step length (preoperative median 52.47 [interquartile range 47.11, 60.33]-postoperative 58.53 [54.63, 64.54] cm; P < 0.0037), walking speed (90.17 [73.98, 108.9]-103.49 [97.66, 117.94] cm/s; P = 0.0022), hip flexor moment (-0.75 [-1.04, -0.51] to -0.94 [-1.07, -0.74] Nm/kg; P = 0.04), and pull-off power generated by hip flexor muscles (H3, 0.68 [0.38, 1]-0.86 [0.72, 1.1] W/kg; P = 0.018). Preoperative joint power declined significantly compared to control parameters. However, 6 months postoperatively, no significant differences were observed. Conclusions: Endovascular therapy for isolated aortoiliac artery lesions improved biomechanical gait parameters in patients with intermittent claudication.

  4. Safety Assessment of Cyanoacrylate Closure for Treatment of Varicose Veins in a Large-Scale National Survey in Japan. International-journal Peer-reviewed

    Michihisa Umetsu, Masayuki Hirokawa, Eri Fukaya, Eiichi Teshima, Hitoshi Kusagawa, Toshiya Nishibe, Makoto Mo, Tomohiro Ogawa

    Journal of vascular surgery. Venous and lymphatic disorders　102160-102160　2024/12/18

    DOI： 10.1016/j.jvsv.2024.102160 　

    More details Close

    OBJECTIVE: Cyanoacrylate closure (CAC) is a minimally invasive technique for treating axial venous reflux. However, the incidence of serious adverse events (AEs) related to CAC is concerning. With an increasing number of patients receiving CAC and insufficient safety data in Japan, this study aimed to investigate the safety profile of CAC, focusing on the types and incidence of AEs. METHODS: A nationwide survey was conducted by the Japanese Regulatory Committee for Endovascular Treatment of Varicose Veins between November 2023 and December 2023. Data were collected from 1,017 institutions, covering 24,209 patients who underwent CAC at 335 institutions between January 2020 and October 2023. Thromboembolism, phlebitis, hypersensitivity reactions, granuloma formation, infection, bleeding, death, and need for glue resection were documented as unfavorable events/outcomes. RESULTS: Venous thromboembolism (VTE) developed in 142 patients (0.59%). Pulmonary embolism, proximal deep vein thrombosis (DVT), and ablation-related thrombus extension (ARTE) developed in 3 (0.01%), 9 (0.04%), and 95 (0.39%) patients, respectively. Localized phlebitis that required additional treatment was observed in 1,656 patients (6.8%). Of the localized hypersensitivity cases, 960 (58%) required oral antihistamines and 268 (16%) required oral and/or intravenous steroids. Furthermore, 65 patients (0.27%) developed systemic hypersensitivity that required systemic steroids. No patients developed a stroke or anaphylaxis. One patient died due to pulmonary embolism. Glue resection was performed in nine patients with delayed infection (n = 4), hypersensitivity reactions (n = 4), or a foreign body granuloma (n = 1). The incidence of hypersensitivity reactions was similar among institutions. However, the incidence of thrombosis-related events significantly differed between the high-volume and low-volume institutions. The incidence of proximal DVT (0.13% vs. 0.01%; p < 0.001; odds ratio [OR], 12.5; 95% confidence interval [CI], 2.6-60.3) and ARTE (0.73% vs. 0.30%; p < 0.001; OR, 2.5; 95% CI, 1.66-3.77) was significantly higher in low-volume institutions than in high-volume centers. CONCLUSIONS: A nationwide survey of CAC for varicose veins in Japan demonstrated that it was a safe procedure with a low rate of serious AEs, such as VTE. However, hypersensitivity reactions requiring steroid administration and systemic allergic reactions were observed in some patients.

  5. Net Clinical Benefit of 12-Month Over 3-Month Edoxaban in Cancer-Associated Isolated Distal Deep Vein Thrombosis. International-journal Peer-reviewed

    Yuji Nishimoto, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Takuma Takada, Yoshito Ogihara, Tatsuya Nishikawa, Nobutaka Ikeda, Yukihito Sato, Takahisa Yamada, Takeshi Kimura

    JACC. CardioOncology　6　(6)　979-981　2024/12

    DOI： 10.1016/j.jaccao.2024.07.019 　

  6. Impact of Anemia on Clinical Outcomes of Patients With Cancer-Associated Isolated Distal Deep Vein Thrombosis Receiving Edoxaban - Insights From the ONCO DVT Study. Peer-reviewed

    Shinya Fujiki, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Tatsuya Nishikawa, Nobutaka Ikeda, Kazunori Otsui, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Ryuki Chatani, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Takeshi Kimura, Takayuki Inomata

    Circulation journal : official journal of the Japanese Circulation Society　2024/09/19

    DOI： 10.1253/circj.CJ-24-0571 　

    More details Close

    BACKGROUND: The ONCO DVT study demonstrated potential benefits of extended edoxaban treatment in patients with isolated distal deep vein thrombosis in terms of thrombotic risk. However, the risk-benefit balance in patients with anemia remains unclear. METHODS AND RESULTS: This prespecified subgroup analysis included 601 patients, divided into anemia (n=402) and no-anemia (n=199) groups. The primary endpoint was symptomatic recurrent venous thromboembolism (VTE) or VTE-related death. Anemia was defined as hemoglobin <12 g/dL for women and <13 g/dL for men. In the anemia subgroup, the primary endpoint occurred in 3 (1.5%) and 17 (8.4%) patients in the 12- and 3-month edoxaban treatment groups, respectively (odds ratio [OR] 0.17; 95% confidence interval [CI] 0.05-0.58), compared with 0 and 5 (4.9%) patients, respectively, in the no-anemia subgroup (P interaction=0.997). Major bleeding occurred in 26 (13.1%) and 17 (8.4%) patients with anemia in the 12- and 3-month edoxaban treatment groups, respectively (OR 1.64; 95% CI 0.86-3.14), compared with 2 (2.1%) and 5 (4.9%) patients without anemia (OR 0.67; 95% CI 0.26-1.73; P interaction=0.13). CONCLUSIONS: Regardless of the presence of anemia, edoxaban treatment for 12 months was superior to treatment for 3 months in reducing thrombotic events, whereas the risk of major bleeding did not differ significantly between the 2 treatment groups.

  7. Utility of the Modified Ottawa Score for Identification of More Preferable Candidates of Extended Anticoagulation therapy in Cancer-associated Isolated Distal Deep Vein Thrombosis: Insight from the ONCO DVT Study. International-journal Peer-reviewed

    Wei Xiong, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Tatsuya Nishikawa, Nobutaka Ikeda, Kazunori Otsui, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Ryuki Chatani, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Koh Ono, Takeshi Kimura

    Journal of thrombosis and haemostasis : JTH　2024/09/14

    DOI： 10.1016/j.jtha.2024.09.003 　

    More details Close

    BACKGROUND: The ONCO DVT study revealed superiority of 12-month relative to 3-month edoxaban treatment for the thrombotic risk in cancer-associated isolated distal deep vein thrombosis (DVT). However, it is unknown whether the superiority could be common in different modified Ottawa score subgroups. METHODS: In this post-hoc subgroup analysis of the ONCO DVT study, we stratified 601 patients into the low (≤-1, N=126), intermediate (0, N=323), and high (≥1, N=152) modified Ottawa score subgroups, and compared clinical outcomes between the 12-month and 3-month edoxaban treatment groups. RESULTS: The cumulative incidence of symptomatic recurrent venous thromboembolism (VTE) or VTE-related death was not different between the 12-month and 3-month edoxaban treatment groups in the low score subgroup (0.0% vs. 2.2%), whereas it was lower in the 12-month than in the 3-month edoxaban treatment group in the intermediate (0.8% vs. 7.6%) and high (3.1% vs. 15.6%) score subgroups. There were no significant differences in the cumulative incidences of the major bleeding between the 12-month and 3-month edoxaban treatment groups in the low (10.1% vs. 7.6%), intermediate (8.8% vs. 5.0%), and high (13.9% vs. 12.6%) score subgroups. CONCLUSIONS: A 12-month compared to 3-month edoxaban treatment showed a lower risk of thrombotic events in patients with cancer-associated isolated distal DVT in the intermediate and high modified Ottawa score subgroups, but not in the low score subgroup, suggesting a limited benefit of extended anticoagulation therapy beyond 3 months in patients with low modified Ottawa score.

  8. Efficacy and Safety of Non-Vitamin K Antagonist Oral Anticoagulants for Japanese Patients With Venous Thromboembolism - The Primary Results From the KUROSIO Study. Peer-reviewed

    Norikazu Yamada, Satoshi Tamaru, Michihisa Umetsu, Kenichi Tsujita, Masato Nakamura, Atsuyuki Watanabe, Mitsuru Yuzaki, Yuki Nishimura, Toru Ogura, Takeshi Yamamoto, Hirono Satokawa, Toru Obayashi, Mashio Nakamura

    Circulation journal : official journal of the Japanese Circulation Society　2024/05/28

    DOI： 10.1253/circj.CJ-23-0954 　

    More details Close

    BACKGROUND: Direct oral anticoagulants (DOACs) are recommended as the first-choice anticoagulation therapy in the acute phase of venous thromboembolism (VTE). However, there is limited real-world data for Japanese VTE patients.Methods and Results: The KUROSIO study (UMIN000023747) was a prospective long-term observational study comprising 1,017 patients with concurrent acute symptomatic pulmonary thromboembolism and proximal deep vein thrombosis (DVT) or isolated calf DVT initially treated with DOACs. After excluding 24 patients, 993 (mean age, 66.3±15.1 years; 58.6% females) were analyzed. The incidences of recurrent symptomatic VTE and major bleeding for up to 52 weeks after diagnosis were 3.2% and 2.2%, respectively. Multivariate analyses revealed chemotherapy and anemia as significant risk factors associated with recurrent symptomatic VTE and major bleeding, respectively. CONCLUSIONS: The efficacy and safety of DOACs in Japanese patients with VTE were determined in this real-world observational study.

  9. Edoxaban for 12 Versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Different Doses: Insights from the ONCO DVT study. International-journal Peer-reviewed

    Ryuki Chatani, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Tatsuya Nishikawa, Nobutaka Ikeda, Kazunori Otsui, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Kazunori Mushiake, Kazushige Kadota, Koh Ono, Takeshi Kimura

    European heart journal. Cardiovascular pharmacotherapy　2024/04/22

    DOI： 10.1093/ehjcvp/pvae028 　

    More details Close

    BACKGROUND: The ONCO DVT study revealed the superiority of 12-month relative to 3-month edoxaban treatment for cancer-associated isolated distal deep vein thrombosis (DVT) regarding the thrombotic risk. METHODS: In this pre-specified subgroup analysis of the ONCO DVT study, we stratified the patients into those with a standard edoxaban dose (60 mg/day; N=151) and those with a reduced edoxaban dose (30 mg/day; N=450) and evaluated the clinical outcomes for the 12-month and 3-month treatments. RESULTS: The cumulative 12-month incidence of symptomatic recurrent venous thromboembolism was lower in the 12-month than 3-month group for both the 60 mg (1.3% vs. 11.6%, P=0.02; odds ratio [OR], 0.12; 95% CI, 0.01-0.97) and 30 mg (1.1% vs. 7.6%, P=0.002; OR, 0.14; 95% CI, 0.03-0.60) edoxaban subgroups, which was consistent across the edoxaban doses without a significant interaction (P =0.90). The 12-month cumulative incidence of major bleeding was higher in the 12-month group than 3-month group for the 60 mg edoxaban subgroup (14.3% vs. 4.4%, P=0.046; OR, 3.61; 95% CI, 0.97-13.52), whereas it did not significantly differ between the two groups for the 30 mg edoxaban subgroup (8.7% vs. 8.6%, P=0.89; OR, 0.97; 95% CI, 0.49-1.91), signaling there was a potential interaction (P=0.07). CONCLUSIONS: A 12-month edoxaban regimen for cancer-associated isolated distal DVT was consistently superior to a 3-month regimen, across the edoxaban doses for the thrombotic risk. However, caution was suggested for the standard dose of edoxaban due to the potential for an increased risk of bleeding with prolonged anticoagulation therapy.

  10. The impact of renal function on clinical outcomes of patients with cancer-associated isolated distal deep vein thrombosis: Insights from the ONCO DVT study. International-journal Peer-reviewed

    Daisuke Sueta, Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Michihisa Umetsu, Yuji Nishimoto, Takuma Takada, Yoshito Ogihara, Tatsuya Nishikawa, Nobutaka Ikeda, Kazunori Otsui, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Ryuki Chatani, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Makoto Mo, Takeshi Kimura, Kenichi Tsujita

    Thrombosis research　235　107-115　2024/02/02

    DOI： 10.1016/j.thromres.2024.01.021 　

    More details Close

    BACKGROUND: The multicenter, open-label, randomized clinical trial ONCO DVT compared 3-month and 12-month edoxaban treatment regimens for isolated distal deep vein thrombosis (DVT) and suggested potential benefits of prolonged edoxaban treatment in terms of thrombotic risk. However, the risk-benefit balance of prolonged edoxaban treatment in patients with renal function remains unclear. OBJECTIVES: To compare the safety and efficacy of 3-month and 12-month edoxaban treatment regimens in patients with cancer-associated isolated distal DVT and different renal functions. METHODS: This pre-specified subgroup analysis of the ONCO DVT study included 601 patients divided into subgroups according to renal function using a 50 mL/min creatinine clearance (Ccr) cutoff. The primary endpoint was symptomatic recurrent venous thromboembolism (VTE) and VTE-related death at 12 months and the major secondary endpoint was major bleeding at 12 months. RESULTS: Among the 601 patients, 131 (21.8 %) comprised the renal dysfunction subgroup. The primary endpoint occurred in 6 (9.7 %) and 1 (1.4 %) patients in the 3-month and 12-month edoxaban groups in the renal dysfunction subgroup, respectively, and in 16 (6.6 %) and 2 (0.9 %) patients in the no renal dysfunction subgroup, respectively. The major secondary endpoint occurred in 9 (14.5 %) and 7 (10.1 %) patients in the 12-month and 3-month edoxaban groups in the renal dysfunction subgroup, and in 13 (5.3 %) and 21 (9.3 %) patients in the no renal dysfunction subgroup, respectively. CONCLUSIONS: A 12-month edoxaban regiment was superior to a 3-month treatment in terms of thrombotic risk irrespective of renal function. A higher bleeding risk was not identified in patients with renal dysfunction who received prolonged edoxaban treatment.

  11. Prophylactic Anticoagulation and Thrombosis in Hospitalized Patients with Clinically Stable COVID-19 at Admission: From the Practice-Based Observational Study Peer-reviewed

    Yugo Yamashita, Sen Yachi, Makoto Takeyama, Yuji Nishimoto, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo

    Annals of Vascular Diseases　17　(1)　1-8　2024

    Publisher: The Editorial Committee of Annals of Vascular Diseases

    DOI： 10.3400/avd.oa.23-00031 　

    ISSN： 1881-641X

    eISSN： 1881-6428

    More details Close

    Objectives: The potential benefit of routine prophylactic anticoagulation for all hospitalized patients with clinically stable coronavirus disease 2019 (COVID-19) is still controversial. Method: The CLOT-COVID Study was a multicenter observational study enrolling 2894 consecutive hospitalized patients with COVID-19. The current study population consisted of 1738 hospitalized patients with mild COVID-19 at admission not requiring oxygen administration, who were divided into 2 groups: patients with prophylactic anticoagulation (n = 326) and those without (n = 1412). Results: Patients with prophylactic anticoagulation had more severe status of the worst severity of COVID-19 during hospitalization compared with those without (mild: 38% versus 82%, moderate: 55% versus 17%, and severe or death at discharge: 6.4% versus 0.7%, P <0.001). During hospitalization, 8 patients (0.5%) developed thrombosis, and the incidences of thrombosis were numerically higher in patients with more severe status of worst severity of COVID-19 during hospitalization (mild: 0.2%, moderate: 1.2%, and severe or death at discharge: 3.2%). Conclusions: Among hospitalized patients with clinically stable COVID-19 at admission, patients who did not worsen in COVID-19 severity after admission rarely developed thrombosis, although patients with worsening of COVID-19 severity after admission more often received prophylactic anticoagulation and might have a higher risk of thrombosis.

  12. Serious Adverse Events with Cyanoacrylate Closure of Varicose Veins: An Initial Report from a Large-Scale National Survey in Japan Peer-reviewed

    Michihisa Umetsu, Masayuki Hirokawa, Eri Fukaya, Eiichi Teshima, Hitoshi Kusagawa, Toshiya Nishibe, Hiroko Nemoto, Makoto Mo, Tomohiro Ogawa

    Annals of Vascular Diseases　17　(1)　21-24　2024

    Publisher: The Editorial Committee of Annals of Vascular Diseases

    DOI： 10.3400/avd.oa.23-00106 　

    ISSN： 1881-641X

    eISSN： 1881-6428

    More details Close

    Objective: Cyanoacrylate closure (CAC) is a minimally invasive technique for the treatment of varicose veins. A recent paper reported serious adverse events (AEs) associated with this use. This triggered an urgent survey to determine the incidence of AEs in Japan. Methods: The CAC-AE survey was sent to all 1,030 institutions authorized for CAC treatments. Cases performed between January 2020 and October 2023 were surveyed. Data on serious AEs and mortality were collected. Results: There were 623 surveys returned. There were 16 cases of proximal deep vein thrombosis, 3 cases of pulmonary embolism (PE), and 0 cases of stroke. Deep vein occlusion due to cyanoacrylate extension was observed in 1 case. Vein resection due to infection was observed in 4 cases. There were 299 cases of localized phlebitis and/or allergic reactions requiring steroid administration. Systemic allergic reactions requiring steroid administration were observed in 66 cases. There was no anaphylaxis associated with cyanoacrylate. There was one postoperative death from PE. Conclusion: This report's intent is to provide real world data on serious AEs following CAC from Japan given current concern over these events. An extensive report investigation of individual complications with analysis including causality will be provided following a full investigation separately.

  13. Revascularization and Digestive Tract Repair in Secondary Aortoenteric Fistula Using a Single-center In situ Revascularization Strategy. International-journal Peer-reviewed

    Daijirou Akamatsu, Fukashi Serizawa, Michihisa Umetsu, Shunya Suzuki, Hitoshi Goto, Michiaki Unno, Takashi Kamei

    Annals of vascular surgery　2023/12/28

    DOI： 10.1016/j.avsg.2023.10.028 　

    More details Close

    OBJECTIVE: Information regarding optimal revascularization and digestive tract repair in secondary aortoenteric fistula (sAEF) remains unclear. Thus, reporting treatment outcomes and presenting comprehensive patient details through a structured treatment approach are necessary to establish a treatment strategy for this rare, complex, and fatal condition. METHODS: We performed a single-center retrospective review of consecutive sAEF managed based on our in situ revascularization (ISR) and intestinal repair strategy. The primary endpoint of this study was all-cause mortality, and secondary endpoints were the incidence of in-hospital complications and midterm reinfections. RESULTS: Between 2007 and 2020, 16 patients with sAEF, including 13 men (81%), underwent ISR and digestive tract repair. The median follow-up duration for all participants was 36 (interquartile range, 6-62) months. Among the participants, 81% (n = 13), 13% (n = 2), and 6% (n = 1) underwent aortic reconstruction with rifampin-soaked grafts, unsoaked Dacron grafts, and femoral veins, respectively. The duodenum was the most commonly involved site in enteric pathology (88%; n = 14), and 57% (n = 8) of duodenal breaks were repaired by a simple closure. Duodenum second part-jejunum anastomosis was performed in 43% of patients (n = 6), and perioperatively, 19% of the patients (n = 3) died. In-hospital complications occurred in 88% patients (n = 14), and the most frequent complication was gastrointestinal. Finally, 81% patients (n = 13) were discharged home. Oral antibiotics were administered for a median duration of 5.7 months postoperatively; subsequently, the participants were followed up carefully. Reinfection was detected in 6% of the patients (n = 1) who underwent reoperation without any complications. The 1- and 3-year overall survival rates of participants were 75% (n = 12) and 75% (n = 9), respectively, and no sAEF-related deaths occurred, except perioperative death. CONCLUSIONS: Surgical intervention with contemporary management based on our vascular strategy and digestive tract procedure may be a durable treatment for sAEF.

  14. 【血管外科疾患の治療と手術手技-消化器・一般外科医が知りたい他科の技と工夫】他科との連携手術 腫瘍・血管合併切除時の要点

    鈴木 峻也, 赤松 大二朗, 戸子台 和哲, 芹澤 玄, 梅津 道久, 亀井 尚

    手術　77　(13)　1923-1932　2023/12

    Publisher: 金原出版(株)

    ISSN： 0037-4423

  15. Edoxaban for 12 Months Versus 3 Months in Cancer Patients With Isolated Distal Deep Vein Thrombosis (ONCO DVT study): An Open-label, Multicenter, Randomized Clinical Trial. International-journal Peer-reviewed

    Yugo Yamashita, Takeshi Morimoto, Nao Muraoka, Takuya Oyakawa, Michihisa Umetsu, Daijirou Akamatsu, Yuji Nishimoto, Yukihito Sato, Takuma Takada, Kentaro Jujo, Yuichiro Minami, Yoshito Ogihara, Kaoru Dohi, Masashi Fujita, Tatsuya Nishikawa, Nobutaka Ikeda, Go Hashimoto, Kazunori Otsui, Kenta Mori, Daisuke Sueta, Yukari Tsubata, Masaaki Shoji, Ayumi Shikama, Yutaka Hosoi, Yasuhiro Tanabe, Ryuki Chatani, Kengo Tsukahara, Naohiko Nakanishi, Kitae Kim, Satoshi Ikeda, Makoto Mo, Yusuke Yoshikawa, Takeshi Kimura

    Circulation　2023/08/28

    DOI： 10.1161/CIRCULATIONAHA.123.066360 　

    More details Close

    Background: The optimal duration of anticoagulation therapy for isolated distal deep vein thrombosis (DVT) in patients with cancer is clinically relevant, but the evidence is lacking. The prolonged anticoagulation therapy could have a potential benefit for prevention of thrombotic events, however, it could also increase the risk of bleeding. Methods: In a multicenter, open-label, adjudicator-blinded, randomized clinical trial at 60 institutions in Japan, we randomly assigned cancer patients with isolated distal DVT, in a 1-to-1 ratio, to receive either a 12-month or 3-month edoxaban treatment. The primary endpoint was a composite of a symptomatic recurrent venous thromboembolism (VTE) or VTE-related death at 12 months. The major secondary endpoint was major bleeding at 12 months, according to the criteria of the International Society on Thrombosis and Hemostasis. The primary hypothesis was that a 12-month edoxaban treatment was superior to a 3-month edoxaban treatment with respect to the primary endpoint. Results: From April 2019 through June 2022, 604 patients were randomized, and after excluding 3 patients who withdrew consent, 601 patients were included in the intention-to-treat population: 296 patients in the 12-month edoxaban group and 305 patients in the 3-month edoxaban group. The mean age was 70.8 years, 28% of the patients were men, and 20% of the patients had symptoms of DVT at baseline. The primary endpoint of a symptomatic recurrent VTE event or VTE-related death occurred in 3 of the 296 patients (1.0%) in the 12-month edoxaban group and in 22 of the 305 (7.2%) in the 3-month edoxaban group (odds ratio, 0.13; 95% CI, 0.03 to 0.44). The major secondary endpoint of major bleeding occurred in 28 of the 296 patients (9.5%) in the 12-month edoxaban group and in 22 of the 305 (7.2%) in the 3-month edoxaban group (odds ratio, 1.34; 95% CI, 0.75 to 2.41). The prespecified subgroups did not affect the estimates on the primary endpoint. Conclusions: In cancer patients with isolated distal DVT, 12 months was superior to 3 months for an edoxaban treatment with respect to the composite outcome of a symptomatic recurrent VTE or VTE-related death.

  16. Type 2 Endoleak Detection After Endovascular Aneurysm Repair: Can Low-Flow Endoleaks Also Be Visualized in Silicon-Photomultiplier-Based Positron Emission Tomography/Computed Tomography Scans? International-journal Peer-reviewed

    Ayaka Harigai, Yoshitaka Toyama, Michihisa Umetsu, Kentaro Takanami, Kei Takase

    Journal of endovascular therapy : an official journal of the International Society of Endovascular Specialists　15266028231185237-15266028231185237　2023/07/02

    DOI： 10.1177/15266028231185237 　

    More details Close

    PURPOSE: To present a novel clinical application of silicon-photomultiplier-based positron emission tomography (SiPM-based PET)/computed tomography (CT), detecting a type II endoleak 5 years after endovascular aneurysm repair (EVAR). TECHNIQUE: SiPM-based PET/CT scans with a standard whole-body protocol were performed for a 73-year-old man with a past medical history of abdominal aortic aneurysms treated with EVAR and currently under investigation of his duodenal papillary carcinoma. The PET/CT demonstrated 18F-fluorodeoxyglucose (FDG) accumulation outside the stent graft in the native sac of the aneurysm. The site of accumulation corresponded to that of the contrast enhancement depicted in the CT angiography taken 1 month earlier. Another CT scan performed 3 months later revealed enlargement of the aneurysm. CONCLUSION: SiPM-based PET/CT, with its superior sensitivity and spatial resolution over conventional PET/CT, can detect type II low-flow endoleaks. CLINICAL IMPACT: Abnormal intra-aneurysmal FDG activity incidentally detected on SiPM-based PET/CT is worthy of attention because it may be indicative of endoleaks. Additional imaging using different modalities should be considered so that the patient would not miss the additional treatment opportunity upon observing sac enlargement. For patients with contraindications for iodine CT contrast media, SiPM-based PET/CT would serve as a suitable alternative.

  17. Clinical Features Comparing Arterial Thrombosis and Venous Thromboembolism in Hospitalized Patients with COVID-19: Result from the CLOT-COVID Study Peer-reviewed

    Michihisa Umetsu, Hajime Kanamori, Koji Murakami, Takuya Shiga, Sen Yachi, Makoto Takeyama, Yuji Nishimoto, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo, Yugo Yamashita

    Annals of Vascular Diseases　16　(2)　115-123　2023/06/25

    Publisher: The Editorial Committee of Annals of Vascular Diseases

    DOI： 10.3400/avd.oa.22-00112 　

    ISSN： 1881-641X

    eISSN： 1881-6428

  18. Presence of Helicobacter cinaedi in Atherosclerotic Abdominal Aortic Aneurysmal Wall. Peer-reviewed

    Shinichiro Horii, Hirofumi Sugawara, Hitoshi Goto, Munetaka Hashimoto, Tetsuro Matsunaga, Daijirou Akamatsu, Yuta Tajima, Michihisa Umetsu, Takaaki Akaike, Takashi Kamei

    The Tohoku journal of experimental medicine　2023/06/15

    DOI： 10.1620/tjem.2023.J049 　

  19. Risk Factors and Impact on Outcomes of Thrombosis in Patients with COVID-19 in Japan: From the CLOT-COVID Study. Peer-reviewed

    Sen Yachi, Makoto Takeyama, Yuji Nishimoto, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo, Yugo Yamashita, On Behalf Of The Clot-Covid Study Investigators

    Annals of vascular diseases　16　(1)　31-37　2023/03/25

    DOI： 10.3400/avd.oa.22-00071 　

    More details Close

    Objectives: The relationship between the thrombotic event and prognosis in patients with coronavirus disease 2019 (COVID-19) has not yet been fully investigated in Japan. Our study aimed to investigate the clinical outcomes and risk factors for thrombosis in hospitalized patients with COVID-19 in Japan. Materials and Methods: We compared the patient characteristics and clinical outcomes among patients with thrombosis (N=55) and those without thrombosis (N=2839) by using a large-scale data of CLOT-COVID study (thrombosis and antiCoaguLatiOn Therapy in patients with COVID-19 in Japan Study: UMIN000045800). Thrombosis included venous thromboembolism, ischemic stroke, myocardial infarction, and systemic arterial thromboembolism. Results: Higher rates of mortality and bleeding events were shown in hospitalized patients with COVID-19 with thrombosis compared to those without thrombosis (all-cause mortality, 23.6% vs. 5.1%, P<0.001; major bleeding, 23.6% vs. 1.6%, P<0.001). Multivariable analysis revealed that the independent risk factors of thrombosis were male sex, D-dimer level on admission>1.0 µg/mL, and moderate and severe COVID-19 status on admission. Conclusions: The development of thrombosis in hospitalized patients with COVID-19 was related to higher mortality and major bleeding, and several independent risk factors for thrombosis could help determine the patient-appropriate treatment for COVID-19.

  20. Anticoagulation Therapy for Pregnancy-Associated Thrombosis: A Retrospective Observational Study. Peer-reviewed

    Michihisa Umetsu, Daijirou Akamatsu, Fukashi Serizawa, Yuta Tajima, Shunya Suzuki, Shinichiro Horii, Norinobu Ogasawara, Hirokazu Takahashi, Yohei Nagaoka, Kota Shimizu, Shunsaku Kimura, Munetaka Hashimoto, Hitoshi Goto, Tetsuo Watanabe, Takashi Kamei

    Annals of vascular diseases　15　(4)　317-323　2022/12/25

    DOI： 10.3400/avd.oa.22-00083 　

    More details Close

    Objectives: Pregnancy-associated deep vein thrombosis (DVT) is a rare disease, and data on anticoagulation therapy are lacking. The present study examined the treatment outcome with unfractionated heparin (UFH) subcutaneous injection in patients with pregnancy-associated DVT. Methods: This single-center, retrospective, observational study enrolled 15 patients with pregnancy-associated DVT treated from January 2014 to April 2021. Results: The median age was 35 years. The median gestation week at onset was 10 (interquartile range is 8-11). All patients presented with painful symptoms with edema. All patients had proximal DVT. Anticoagulation therapy using UFH was performed in 14 patients. The median continuous dose of heparin was 18,750 U/day, and the median subcutaneous dose was 20,000 U/day. During the outpatient period, the values of activated partial thromboplastin time fluctuated wildly, but the fibrin monomer complex level remained consistently low. There were two mild bleeding complications, but neither prevented the continuation of anticoagulation therapy. During delivery, thrombi were not detected in 10 of 13 patients (77%), whereas three patients (23%) exhibited regression without resolution of the thrombus. Conclusion: Anticoagulation using UFH subcutaneous injection was safely performed in patients with pregnancy-associated DVT without serious complications or progression of thrombosis.

  21. Real-World Management of Pharmacological Thromboprophylactic Strategies for COVID-19 Patients in Japan Peer-reviewed

    Hiroya Hayashi, Yasuhiro Izumiya, Daiju Fukuda, Fumiaki Wakita, Yasumitsu Mizobata, Hiromichi Fujii, Sen Yachi, Makoto Takeyama, Yuji Nishimoto, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo, Yugo Yamashita

    JACC: Asia　2　(7)　897-907　2022/12

    Publisher: Elsevier BV

    DOI： 10.1016/j.jacasi.2022.09.005 　

    ISSN： 2772-3747

  22. Mortality-Associated Risk Factors in Hospitalized COVID-19 Patients in Japan: Findings of the CLOT-COVID Study. Peer-reviewed

    Makoto Takeyama, Sen Yachi, Yuji Nishimoto, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo, Yugo Yamashita

    Journal of epidemiology　33　(3)　150-157　2022/11/12

    DOI： 10.2188/jea.JE20220201 　

    More details Close

    BACKGROUND: Reports of mortality-associated risk factors in patients with coronavirus disease (COVID-19) are limited. METHODS: We evaluated the clinical features that were associated with mortality among patients who died during hospitalization (N=158) and those who were alive at discharge (N=2,736) from the large-scale, multicenter, retrospective, observational cohort CLOT-COVID study enrolled consecutively hospitalized COVID-19 patients from 16 centers in Japan from April to September 2021. Data from 2,894 hospitalized COVID-19 participants of the CLOT-COVID study were analyzed in this study. RESULTS: Patients who died were older (71.1 years versus 51.6 years, P<0.001), had higher median D-dimer values on admission (1.7 μg/mL versus 0.8 μg/mL, P<0.001), and had more comorbidities. On admission, the patients who died had more severe COVID-19 than did those who survived (mild: 16% versus 63%, moderate: 47% versus 31%, and severe: 37% versus 6.2%, P<0.001). In patients who died, the incidence of thrombosis and major bleeding during hospitalization was significantly higher than that in those who survived (thrombosis: 8.2% vs. 1.5%, P<0.001; major bleeding: 12.7% vs. 1.4%, P<0.001). Multivariable logistic regression analysis revealed that age >70 years, high D-dimer values on admission, heart disease, active cancer, higher COVID-19 severity on admission, and development of major bleeding during hospitalization were independently associated with a higher mortality risk. CONCLUSIONS: This large-scale observational study in Japan identified several independent risk factors for mortality in hospitalized patients with COVID-19 that could facilitate appropriate risk stratification of patients with COVID-19.

  23. Incidence, risk factors, and clinical impact of major bleeding in hospitalized patients with COVID-19: a sub-analysis of the CLOT-COVID Study. International-journal Peer-reviewed

    Junichi Nakamura, Ichizo Tsujino, Sen Yachi, Makoto Takeyama, Yuji Nishimoto, Satoshi Konno, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo, Yugo Yamashita

    Thrombosis journal　20　(1)　53-53　2022/09/20

    DOI： 10.1186/s12959-022-00414-x 　

    More details Close

    BACKGROUND: The coronavirus disease 2019 (COVID-19) causes extensive coagulopathy and a potential benefit of anticoagulation therapy has been documented for prevention of thromboembolic events. Bleeding events has also been reported as a notable complication; whereas, the incidence, risks, and clinical impact of bleeding remain unclear. METHOD: The CLOT-COVID Study was a nationwide, retrospective, multicenter cohort study on consecutive hospitalized patients with COVID-19 in Japan between April 2021 and September 2021. In this sub-analysis, we compared the characteristics of patients with and without major bleeding; moreover, we examined the risk factors for and clinical impact of bleeding events. RESULTS: Among 2882 patients with COVID-19, 57 (2.0%) had major bleeding. The incidence of major bleeding increased with COVID-19 severity as follows: 0.5%, 2.3%, and 12.3% in patients with mild, moderate, and severe COVID-19, respectively. COVID-19 severity, history of major bleeding, and anticoagulant type/dose were independently and additively associated with the bleeding incidence. Compared with patients without major bleeding, those with major bleeding exhibited a longer duration of hospitalization (9 [6-14] vs 28 [19-43] days, P < 0.001) and higher mortality during hospitalization (4.9% vs. 35.1%, P < 0.001). CONCLUSIONS: In the real-world clinical practice, the incidence of major bleeding was not uncommon, especially in patients with severe COVID-19. Independent risk factors for major bleeding included history of major bleeding, COVID-19 severity, and anticoagulant use, which could be associated with poor clinical outcomes including higher mortality. Precise recognition of the risks for bleeding may be helpful for an optimal use of anticoagulants and for better outcomes in patients with COVID-19.

  24. Influence of obesity on incidence of thrombosis and disease severity in patients with COVID-19: From the CLOT-COVID study. International-journal Peer-reviewed

    Yoshito Ogihara, Sen Yachi, Makoto Takeyama, Yuji Nishimoto, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo, Yugo Yamashita

    Journal of cardiology　81　(1)　105-110　2022/08/29

    DOI： 10.1016/j.jjcc.2022.08.011 　

    More details Close

    BACKGROUND: The influence of obesity on the development of thrombosis and severity of coronavirus disease 2019 (COVID-19) remains unclear. METHOD: The CLOT-COVID study was a retrospective multicenter cohort study enrolling 2894 consecutive hospitalized patients with COVID-19 between April 2021 and September 2021 among 16 centers in Japan. The present study consisted of 2690 patients aged over 18 years with available body mass index (BMI), who were divided into an obesity group (BMI ≥30) (N = 457) and a non-obesity group (BMI <30) (N = 2233). RESULTS: The obesity group showed more severe status of COVID-19 at admission compared with the non-obesity group. The incidence of thrombosis was not significantly different between the groups (obesity group: 2.6 % versus non-obesity group: 1.9 %, p = 0.39), while the incidence of a composite outcome of all-cause death, or requirement of mechanical ventilation or extracorporeal membrane oxygenation during hospitalization was significantly higher in the obesity group (20.1 % versus 15.0 %, p < 0.01). After adjusting confounders in the multivariable logistic regression model, the risk of obesity relative to non-obesity for thrombosis was not significant (adjusted OR, 1.39; 95 % CI, 0.68-2.84, p = 0.37), while the adjusted risk of obesity relative to non-obesity for the composite outcome was significant (adjusted OR, 1.85; 95 % CI, 1.39-2.47, p < 0.001). CONCLUSIONS: In the present large-scale observational study, obesity was not significantly associated with the development of thrombosis during hospitalization; however, it was associated with severity of COVID-19.

  25. Significant Impact of Age on Mortality and Non-significant Impact of Age on Thrombosis and Major Bleeding in Patients with COVID-19: From the CLOT-COVID Study. Peer-reviewed

    Yugo Yamashita, Sen Yachi, Makoto Takeyama, Yuji Nishimoto, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo

    Journal of atherosclerosis and thrombosis　30　(6)　624-635　2022/07/29

    DOI： 10.5551/jat.63702 　

    More details Close

    AIM: There is scarce data on the impact of age on clinical outcomes in patients with coronavirus disease 2019 (COVID-19). METHOD: The CLOT-COVID Study was a retrospective, multicenter cohort study enrolling 2894 consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021. We divided the entire cohort into five groups according to age strata; -19, 20-39, 40-59, 60-79, and 80- years. RESULTS: Most patients under 19 had mild COVID-19 on admission (99%), while older patients had more severe COVID-19. The incidence rates of clinical outcomes during hospitalization in patients aged ≤ 19, 20-39, 40-59, 60-79, and 80 ≥ years were 0.0%, 0.5%, 2.2%, 2.7%, and 1.5% for thrombosis; 0.0%, 1.2%, 1.5%, 3.4%, and 2.0% for major bleeding; and 0.0%, 0.4%, 2.0%, 12.1%, and 16.8% for all-cause death, respectively. In the stratified analysis according to COVID-19 severity on admission, the incidences of thrombosis were generally higher among patients with more severe status, although those were not significantly different among age strata in all sub-types of COVID-19 severity. However, the incidences of all-cause death were significantly higher with increasing age in all sub-types of COVID-19 severity. CONCLUSIONS: In the current large observational study of patients with COVID-19, the risk of mortality became markedly higher with increased age. However, the risks of thrombosis and major bleeding did not necessarily increase as age increases, which seemed to be consistent irrespective of COVID-19 severity on admission.

  26. Association Between the Development of Thrombosis and Worsening of Disease Severity in Patients With Moderate COVID-19 on Admission - From the CLOT-COVID Study. Peer-reviewed

    Satoshi Ikeda, Yuki Ueno, Koji Maemura, Sen Yachi, Makoto Takeyama, Yuji Nishimoto, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Michihisa Umetsu, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo, Yugo Yamashita

    Circulation journal : official journal of the Japanese Circulation Society　87　(3)　448-455　2022/07/01

    DOI： 10.1253/circj.CJ-22-0252 　

    More details Close

    BACKGROUND: The worsening of coronavirus disease 2019 (COVID-19) severity is a critical issue in current clinical settings and may be associated with the development of thrombosis.Methods and Results: This study used patient data obtained in the CLOT-COVID study, a retrospective multicenter cohort study. The demographics of patients with moderate COVID-19 on admission with and without worsened severity during hospitalization were compared and predictors were identified. Of 927 patients with moderate COVID-19 on admission, 182 (19.6%) had worsened severity during hospitalization. Patients with worsening of severity were older, more likely to have hypertension, diabetes, heart disease, and active cancer, and more likely to use pharmacological thromboprophylaxis. Patients with worsening of severity had higher D-dimer levels on admission and were more likely to develop thrombosis and major bleeding during hospitalization than those without worsening. Increased age (odds ratio [OR]: 1.02, 95% confidence interval [CI]: 1.01-1.03, P=0.005), diabetes (OR: 1.63, 95% CI: 1.11-2.33, P=0.012), D-dimer levels >1.0 μg/mL on admission (OR: 2.10, 95% CI: 1.45-3.03, P<0.001), and thrombosis (OR: 6.28, 95% CI: 2.72-14.53, P<0.001) were independently associated with worsening of COVID-19 severity. CONCLUSIONS: Approximately 20% of patients with moderate COVID-19 had worsened severity during hospitalization. Increased age, diabetes, D-dimer levels >1.0 μg/mL on admission, and the development of thrombosis during hospitalization were significantly associated with worsened COVID-19 severity.

  27. Transfusion-Related Acute Lung Injury Type I Immediately after Open Surgical Repair for Abdominal Aortic Aneurysm. Peer-reviewed

    Kota Shimizu, Michihisa Umetsu, Hitoshi Goto, Takuya Fujimine, Daijirou Akamatsu, Takashi Kamei

    Annals of vascular diseases　15　(2)　146-149　2022/06/25

    DOI： 10.3400/avd.cr.21-00143 　

    More details Close

    A 68-year-old man underwent open surgical repair for an abdominal aortic aneurysm. The intraoperative period had no adverse events until postoperative extubation. His SpO2 rapidly dropped, and severe acute lung edema developed. He had cardiopulmonary arrest. Cardiogenic pulmonary edema and other diseases were ruled out. He was finally diagnosed with transfusion-related acute lung injury (TRALI) type I. Intensive care with ventilator management and continuous adrenaline administration was provided. His condition gradually improved, and he was discharged without any sequelae. Surgical cases requiring blood transfusion should be carefully monitored, and prompt action should be taken when TRALI occurs.

  28. Therapeutic-Dose vs. Prophylactic-Dose Anticoagulation Therapy for Critically Ill Patients With COVID-19 in a Practice-Based Observational Study. Peer-reviewed

    Yugo Yamashita, Sen Yachi, Makoto Takeyama, Yuji Nishimoto, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo

    Circulation journal : official journal of the Japanese Circulation Society　86　(7)　1137-1142　2022/06/03

    DOI： 10.1253/circj.CJ-22-0209 　

    More details Close

    BACKGROUND: The potential benefit of therapeutic-dose anticoagulation for critically ill patients with coronavirus disease 2019 (COVID-19) is still controversial.Methods and Results: In the CLOT-COVID study, 225 patients with severe COVID-19 on admission requiring mechanical ventilation or extracorporeal membrane oxygenation were divided into patients with therapeutic-dose anticoagulation (N=110) and those with prophylactic-dose anticoagulation (N=115). There was no significant difference in the incidence of thrombosis between the groups (9.1% vs. 7.8%, P=0.73). CONCLUSIONS: Among a cohort of critically ill patients with COVID-19, approximately half received therapeutic-dose anticoagulation, although it did not show a potential benefit compared with prophylactic-dose anticoagulation.

  29. D-Dimer Values and Venous Thromboembolism in Patients With COVID-19 in Japan - From the CLOT-COVID Study. Peer-reviewed

    Nobutaka Ikeda, Sen Yachi, Makoto Takeyama, Yuji Nishimoto, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo, Yugo Yamashita

    Circulation reports　4　(5)　215-221　2022/05/10

    DOI： 10.1253/circrep.CR-22-0022 　

    More details Close

    Background: To date, there are no large-scale data on the association between D-dimer levels at admission and the occurrence of venous thromboembolism (VTE) in Japanese patients with coronavirus disease 2019 (COVID-19). Methods and Results: The CLOT-COVID study was a retrospective, multicenter cohort study enrolling consecutive hospitalized patients with COVID-19 across 16 centers in Japan from April 2021 to September 2021. Among 2,894 enrolled patients, 2,771 (96%) had D-dimer levels measured at admission. Patients were divided into 3 groups based on tertiles of D-dimer levels at admission (1st tertile, D-dimer ≤0.5 μg/mL, n=949; 2nd tertile, D-dimer 0.51-1.09 μg/mL, n=894; 3rd tertile, D-dimer ≥1.1 μg/mL, n=928). The higher the tertile group, the more severe the COVID-19 status at admission. The incidence of VTE during hospitalization was highest in the 3rd tertile group (1st tertile, 0.3%; 2nd tertile, 0.3%; 3rd tertile, 3.6%; P<0.001). Even after adjusting for confounders in the multivariable logistic regression model, the higher D-dimer levels in the 3rd tertile (≥1.1 μg/mL) were independently associated with a higher risk of VTE during hospitalization (adjusted odds ratio 4.83 [95% confidence interval 1.93-12.11; P<0.001]; reference=1st tertile). Conclusions: Higher D-dimer levels at admission were associated with a higher risk of VTE events during hospitalization in Japanese patients with COVID-19. This could be helpful in determining patient-specific anticoagulation management strategies for COVID-19 in Japan.

  30. Prospective clinical study for claudication after endovascular aneurysm repair involving hypogastric artery embolization. Peer-reviewed

    Shunya Suzuki, Daijirou Akamatsu, Hitoshi Goto, Takaaki Kakihana, Hirofumi Sugawara, Ken Tsuchida, Yoshitaro Yoshida, Michihisa Umetsu, Takashi Kamei, Michiaki Unno

    Surgery today　2022/05/09

    DOI： 10.1007/s00595-022-02502-x 　

    More details Close

    PURPOSE: This prospective study aimed to assess the prognosis of claudication after endovascular aneurysm repair (EVAR) involving hypogastric artery (HGA) embolization. METHODS: Patients who were scheduled to undergo EVAR involving bilateral or unilateral HGA embolization (BHE or UHE, respectively) between May 2017 and January 2019 were included in this study. Patients underwent the walk test preoperatively, one week postoperatively, and monthly thereafter for six months. The presence of claudication and the maximum walking distance (MWD) were recorded. A near-infrared spectroscopy monitor was placed on the buttocks, and the recovery time (RT) was determined. A walking impairment questionnaire (WIQ) was completed to determine subjective symptoms. RESULTS: Of the 13 patients who completed the protocol, 12 experienced claudication in the 6-min walk test. The MWD was significantly lower at one week postoperatively than preoperatively. The claudication prevalence was significantly higher at five and six months postoperatively after BHE than after UHE. BHE was associated with longer RTs and lower WIQ scores than UHE. CONCLUSIONS: We noted a trend in adverse effects on the gluteal circulation and subjective symptoms ameliorating within six months postoperatively, with more effects being associated with BHE than with UHE. These findings should be used to make decisions concerning management strategies for HGA reconstruction.

  31. The current status of thrombosis and anticoagulation therapy in patients with COVID-19 in Japan: From the CLOT-COVID study. International-journal Peer-reviewed

    Yuji Nishimoto, Sen Yachi, Makoto Takeyama, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo, Yugo Yamashita

    Journal of cardiology　80　(4)　285-291　2022/04/05

    DOI： 10.1016/j.jjcc.2022.03.015 　

    More details Close

    BACKGROUND: Data on thrombosis and current real-world management strategies for anticoagulation therapy are scarce but important for understanding current issues and unmet needs of an optimal management of patients with coronavirus disease 2019 (COVID-19). METHOD: The CLOT-COVID Study (thrombosis and antiCoaguLatiOn Therapy in patients with COVID-19 in Japan Study: UMIN000045800) was a retrospective, multicenter cohort study enrolling consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021, and we tried to capture the status of the patients in the fourth and fifth waves of the COVID-19 infections in Japan. We enrolled consecutive hospitalized patients who were diagnosed with COVID-19 and had a positive polymerase chain reaction test obtained from the hospital databases. RESULTS: Among 2894 patients with COVID-19, 1245 (43%) received pharmacological thromboprophylaxis. The proportion of pharmacological thromboprophylaxis increased according to the severity of the COVID-19 in 9.8% with mild COVID-19, 61% with moderate COVID-19, and 97% with severe COVID-19. The types and doses of anticoagulants varied widely across the participating centers. During the hospitalization, 38 patients (1.3%) and 126 (4.4%) underwent ultrasound examinations for the lower extremities and contrast-enhanced computed tomography examinations, respectively, and 55 (1.9%) developed thrombosis, mostly venous thromboembolism (71%). The incidence of thrombosis increased according to the severity of the COVID-19 in 0.2% with mild COVID-19, 1.4% with moderate COVID-19, and 9.5% with severe COVID-19. Major bleeding occurred in 57 patients (2.0%) and 158 (5.5%) died, and 81% of them were due to respiratory failure from COVID-19 pneumonia. CONCLUSIONS: In the present large-scale observational study, pharmacological thromboprophylaxis for hospitalized patients with COVID-19 was common especially in patients with severe COVID-19, and management strategies varied widely across the participating centers. The overall incidence of thrombosis was substantially low with an increased incidence according to the severity of the COVID-19.

  32. Influence of sex on development of thrombosis in patients with COVID-19: From the CLOT-COVID study. International-journal Peer-reviewed

    Yugo Yamashita, Sen Yachi, Makoto Takeyama, Yuji Nishimoto, Ichizo Tsujino, Junichi Nakamura, Naoto Yamamoto, Hiroko Nakata, Satoshi Ikeda, Michihisa Umetsu, Shizu Aikawa, Hiroya Hayashi, Hirono Satokawa, Yoshinori Okuno, Eriko Iwata, Yoshito Ogihara, Nobutaka Ikeda, Akane Kondo, Takehisa Iwai, Norikazu Yamada, Tomohiro Ogawa, Takao Kobayashi, Makoto Mo

    Thrombosis research　213　173-178　2022/03/31

    DOI： 10.1016/j.thromres.2022.03.023 　

    More details Close

    INTRODUCTION: There has been limited data on the influence of sex on development of thrombosis in patients with coronavirus disease 2019 (COVID-19). MATERIALS AND METHODS: The CLOT-COVID Study was a retrospective, multicenter cohort study enrolling 2894 consecutive hospitalized patients with COVID-19 among 16 centers in Japan from April 2021 to September 2021. We divided the entire cohort into the men (N = 1885) and women (N = 1009) groups. RESULTS: There were no significant differences in D-dimer levels at admission between men and women. Men had more severe status of the COVID-19 at admission compared with women (Mild: 57% versus 66%, Moderate: 34% versus 29%, and Severe: 9.1% versus 5.7%, P < 0.001). Men more often received pharmacological thromboprophylaxis than women (47% versus 35%, P < 0.001). During the hospitalization, men more often developed thrombosis than women (2.5% [95%CI, 1.9-3.3%] versus 0.8% [95%CI, 0.4-1.6%], P = 0.001). Men had numerically higher incidences of thrombosis than women in all subgroups of the worst severity of COVID-19 during the hospitalization (Mild: 0.3% versus 0.0%, Moderate: 1.6% versus 1.0%, and Severe: 11.1% versus 4.3%). Even after adjusting confounders in the multivariable logistic regression model, the excess risk of men relative to women remained significant for thrombosis (adjusted OR, 2.51; 95%CI, 1.16-5.43, P = 0.02). CONCLUSIONS: In the current large observational study of patients with COVID-19, men had more severe status of the COVID-19 than women, and the risk of development of thrombosis was higher in men compared with women, which could be helpful in determining the patient-specific optimal management strategies for COVID-19.

  33. Successful Treatment of Giant Common and Proper Hepatic Artery Aneurysm Complicating Autosomal Dominant Polycystic Kidney Disease1. International-journal Peer-reviewed

    Michihisa Umetsu, Daijirou Akamatsu, Hitoshi Goto, Munetaka Hashimoto, Fukashi Serizawa, Yuta Tajima, Shinichiro Horii, Norinobu Ogasawara, Hirokazu Takahashi, Yohei Nagaoka, Takashi Kamei

    Annals of vascular surgery　83　379.e1-379.e5　2022/03/23

    DOI： 10.1016/j.avsg.2022.03.011 　

    More details Close

    Hepatic artery aneurysms (HAAs) complicating autosomal dominant polycystic kidney disease (ADPKD) are extremely rare. Owing to the large number of renal cysts in ADPKD, ingenuity is required to safely perform surgery for HAA. Here, we present the case of a 60-year-old man with a common and proper HAA of >60 mm complicated with ADPKD. In this patient, difficulty in maintaining the field of view was expected during surgery. Hence, we performed a hybrid approach with celiac-to-right hepatic artery bypass by puncturing the femoral artery and cannulating the splenic artery to allow celiac-splenic artery balloon occlusion in case of rupture. More than 5 years postoperatively, the graft is patent without intervention.

  34. Arterio-Enteric FistulaにおけるBridge Therapyとして有効であったステントグラフトの使用経験 Peer-reviewed

    堀井 晋一良, 赤松 大二朗, 後藤 均, 芹澤 玄, 吉田 良太朗, 田島 悠太, 梅津 道久, 高橋 宏和, 小笠原 紀信, 長岡 洋平, 三塚 浩二, 大沼 忍, 海野 倫明, 亀井 尚

    血管外科　40　(1)　82-88　2021/11

    Publisher: 血管外科症例検討会

  35. Incidence and Clinical Features of Venous Thromboembolism in Hospitalized Patients With Coronavirus Disease 2019 (COVID-19) in Japan. Peer-reviewed

    Yugo Yamashita, Yuuki Maruyama, Hirono Satokawa, Yuji Nishimoto, Ichizo Tsujino, Hideki Sakashita, Hiroko Nakata, Yoshinori Okuno, Yoshito Ogihara, Sen Yachi, Naoki Toya, Masami Shingaki, Satoshi Ikeda, Naoto Yamamoto, Shizu Aikawa, Nobutaka Ikeda, Hiroya Hayashi, Shingo Ishiguro, Eriko Iwata, Michihisa Umetsu, Akane Kondo, Takehisa Iwai, Takao Kobayashi, Makoto Mo, Norikazu Yamada

    Circulation journal : official journal of the Japanese Circulation Society　85　(12)　2208-2214　2021/05/20

    DOI： 10.1253/circj.CJ-21-0169 　

    More details Close

    BACKGROUND: Coronavirus disease 2019 (COVID-19) reportedly causes venous thromboembolism (VTE), but the status of this complication in Japan was unclear.Methods and Results:The VTE and COVID-19 in Japan Study is a retrospective, multicenter cohort study enrolling hospitalized patients with COVID-19 who were evaluated with contrast-enhanced computed tomography (CT) examination at 22 centers in Japan between March 2020 and October 2020. Among 1,236 patients with COVID-19, 45 (3.6%) were evaluated with contrast-enhanced CT examination. VTE events occurred in 10 patients (22.2%), and the incidence of VTE in mild, moderate, and severe COVID-19 was 0%, 11.8%, and 40.0%, respectively. COVID-19 patients with VTE showed a higher body weight (81.6 vs. 64.0 kg, P=0.005) and body mass index (26.9 vs. 23.2 kg/m2, P=0.04), and a higher proportion had a severe status for COVID-19 compared with those without. There was no significant difference in the proportion of patients alive at discharge between patients with and without VTE (80.0% vs. 88.6%, P=0.48). Among 8 pulmonary embolism (PE) patients, all were low-risk PE. CONCLUSIONS: Among a relatively small number of patients undergoing contrast-enhanced CT examination in Japanese real-world clinical practice, there were no VTE patients among those with mild COVID-19, but the incidence of VTE seemed to be relatively high among severe COVID-19 patients, although all PE events were low-risk without significant effect on mortality risk.

  36. Comparison of Edoxaban and Warfarin for the Treatment of Cancer-Associated Venous Thromboembolism - A Retrospective Observational Study. Peer-reviewed

    Hitoshi Goto, Michihisa Umetsu, Daijirou Akamatsu, Hirofumi Sugawara, Ken Tsuchida, Yoshitaro Yoshida, Shunya Suzuki, Takashi Kamei

    Circulation journal : official journal of the Japanese Circulation Society　2021/03/09

    DOI： 10.1253/circj.CJ-20-0713 　

    More details Close

    BACKGROUND: Because anticoagulant drugs for ambulatory patients with cancer-associated venous thromboembolism (CAT) are limited to warfarin and direct oral anticoagulants (DOACs) in Japan, it is important to assess the outcomes of both drugs.Methods and Results:We retrospectively assessed the outcomes of CAT patients who were treated with warfarin or edoxaban between 2011 and 2017. The assessment was limited to the duration of anticoagulant administration. CAT patients who did not receive anticoagulation therapy were also compared with the warfarin and edoxaban groups. We enrolled 111 CAT patients treated with warfarin (n=58, mean age 62.6 years, mean time in therapeutic range [TTR] % 61.1) or edoxaban (n=53, mean age 64.6 years). Although venous thromboembolism (VTE) recurred in 2 warfarin-treated patients, the 2 treatment groups were not significantly different (P=0.18). Bleeding during anticoagulation therapy occurred in 6 warfarin-treated patients (2 with major bleeding) and in 5 edoxaban-treated patients (no major bleeding) (P=1.0). The non-anticoagulation group (n=37) showed a high recurrence rate (P<0.01) compared with the anticoagulant group. CONCLUSIONS: This study showed that warfarin and edoxaban are equally effective in preventing VTE recurrence and bleeding. However, warfarin control in CAT patients presented some difficulties. This study also demonstrated the efficacy of anticoagulant drugs, compared with no anticoagulation, for CAT patients to prevent VTE recurrence.

  37. B型大動脈解離による腸管虚血に対する血行再建術後に腸閉塞および小腸出血を来した1例 Peer-reviewed

    高橋 宏和, 後藤 均, 赤松 大二朗, 熊谷 紀一郎, 鈴木 佑輔, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 小笠原 紀信, 亀井 尚

    血管外科　39　(1)　70-76　2020/11

    Publisher: 血管外科症例検討会

  38. Detection of Macrophage Localization in the Abdominal Aortic Aneurysm Wall using Ex Vivo Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging. International-journal Peer-reviewed

    Michihisa Umetsu, Hitoshi Goto, Yasuhiro Nakamura, Hideki Ota, Takuya Shimizu, Munetaka Hashimoto, Daijirou Akamatsu, Takashi Kamei

    Annals of vascular surgery　58　(6)　e788-e788　2020/05/18

    DOI： 10.1016/j.avsg.2020.04.067 　

    More details Close

    INTRODUCTION: Macrophages in the aneurysmal wall play an important role in the pathogenesis of abdominal aortic aneurysms (AAAs). Superparamagnetic iron oxide (SPIO) is a macrophage-specific contrast agent that results in negative enhancement on magnetic resonance imaging (MRI). SPIO-enhanced MRI targeting the intraluminal thrombus of AAAs has been previously reported. However, macrophages in the media and adventitia of AAA wall have not been investigated in detail. This study aimed to evaluate macrophage localization using SPIO-enhanced MRI in the media and adventitia of AAA wall, as macrophages play a crucial role in AAA pathogenesis. METHODS: Here we included study and control patients planning to undergo open surgery for AAA. While study patients received SPIO injection 2 days preoperatively (the SPIO group, n = 7), the control patients did not receive this injection (the control group). Ex vivo MRI was performed on the harvested AAA wall in the SPIO group during the surgery. The concordance between the number of macrophages and berlin blue-stained areas was histologically evaluated in both groups. Moreover, the concordance between regions of interest in MR images and berlin blue-stained areas was evaluated. RESULTS: The proportion of berlin blue-stained macrophages was higher in the SPIO group (0.93, interquartile range [IQR] 0.83-0.95) than in the control group (0.03, IQR 0.026-0.11) (p < 0.05), indicating uptake of SPIO by macrophages in the AAA wall. A significant positive correlation was found between the number of berlin blue-stained macrophages and berlin blue-stained areas using Kendall rank correlation coefficient in the SPIO group (τ = 0.58, p < 0.05). Significant correlations were found in the distributions of the region of interest of SPIO-enhanced MRI and berlin blue-stained areas in the media and adventitia in five of seven patients. CONCLUSION: Macrophages present in the media and adventitia of the AAA wall showed an uptake of the SPIO contrast agent injected 2 days prior, which were then detected by ex vivo MRI. This suggests that SPIO-enhanced magnetic resonance images help detect the localization of macrophages on the AAA wall, indicating its potential to serve as a novel index for AAA pathogenesis.

  39. Midaortic Syndrome due to Takayasu Arteritis in a Child with Acute Decompensated Cardiac Failure Managed by an Emergency Axillo-External Iliac Artery Bypass: A Follow-Up Case Report of Long-Term Outcomes. International-journal Peer-reviewed

    Hirofumi Sugawara, Hitoshi Goto, Daijirou Akamatsu, Yoh Hamada, Ken Tsuchida, Yoshitaro Yoshida, Michihisa Umetsu, Shunya Suzuki, Shinichiro Horii, Norinobu Ogasawara, Hirokazu Takahashi, Tetsuo Watanabe, Takashi Kamei

    Annals of vascular surgery　64　408.e5-408.e9　2020/04

    DOI： 10.1016/j.avsg.2019.09.026 　

    More details Close

    Midaortic syndrome (MAS) is characterized by a diffuse narrowing of the distal thoracic or abdominal aorta and is concomitant with various etiologies. The common symptoms of MAS include severe hypertension or arterial insufficiency distal to the stenosis. This includes lower extremity claudication and heart failure due to afterload mismatch. We present the case of an 8-year-old girl who developed acute decompensated cardiac, respiratory, and renal failures because of the occlusion of the descending aorta secondary to Takayasu arteritis (TA). Although thoracoabdominal-aortic bypass is usually performed for patients with MAS, the procedure was considered too invasive, given the patient's condition. Therefore, we performed an emergency axillo-external iliac artery bypass for revascularization. Subsequently, organ failure improved and she was discharged. At postoperative 10 years, an asymptomatic pseudoaneurysm was detected at the distal anastomosis, for which revision surgery was performed. Overall, the long-term prognosis was satisfactory, suggesting that this procedure is less invasive and effective for treatment of MAS due to TA, in emergencies.

  40. Long-Term Outcomes of Surgical Treatment by In Situ Graft Reconstruction for Infected Abdominal Aortic Aneurysm. Peer-reviewed

    Hashimoto M, Goto H, Akamatsu D, Shimizu T, Tsuchida K, Kawamura K, Tajima Y, Umetsu M, Suzuki S, Kamei T

    Annals of vascular diseases　12　(4)　524-529　2019/12

    DOI： 10.3400/avd.oa.19-00099 　

  41. 緊急血行再建術を施行した下肢血管損傷4例 Peer-reviewed

    吉田 良太朗, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 亀井 尚

    血管外科　38　(1)　69-74　2019/11

    Publisher: 血管外科症例検討会

  42. 【静脈疾患に対する手術手技】大腿静脈採取

    赤松 大二朗, 後藤 均, 宮城 重人, 中西 史, 土田 憲, 菅原 宏文, 梅津 道久, 鈴木 峻也, 橋本 宗敬, 清水 拓也, 中野 善之, 田島 悠太, 小ヶ口 恭介, 渡辺 徹雄, 三井 一浩, 亀井 尚

    血管外科　38　(1)　28-35　2019/11

    Publisher: 血管外科症例検討会

  43. 【肝胆膵の救急疾患とその最新の治療現場】古典的な肝胆膵での救急疾患とその最新治療 上腸間膜動脈閉塞・解離に対するアプローチ Peer-reviewed

    菅原 宏文, 後藤 均, 赤松 大二朗, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 海野 倫明, 亀井 尚

    肝・胆・膵　79　(4)　651-658　2019/10

    Publisher: (株)アークメディア

    ISSN： 0389-4991

  44. Long-Term Outcomes of Acute Limb Ischemia: A Retrospective Analysis of 93 Consecutive Limbs. Peer-reviewed

    Michihisa Umetsu, Daijirou Akamatsu, Hitoshi Goto, Masato Ohara, Munetaka Hashimoto, Takuya Shimizu, Hirofumi Sugawara, Ken Tsuchida, Yoshitaro Yoshida, Yuta Tajima, Shunya Suzuki, Shinichiro Horii, Tetsuo Watanabe, Shigehito Miyagi, Michiaki Unno, Takashi Kamei

    Annals of vascular diseases　12　(3)　347-353　2019/09/25

    DOI： 10.3400/avd.oa.19-00018 　

    More details Close

    Objective: To examine the medium- to long-term outcomes of acute limb ischemia (ALI), which are unclear at present. Methods: We analyzed 93 consecutive limbs in 77 patients with ALI between January 2005 and December 2015 treated at our vascular center. We categorized the cases into four groups according to etiology (embolism, thrombosis, graft thrombosis, and dissection groups) to assess survival, limb salvage, and freedom from re-intervention rates. Results: The mean age at onset was 72±15 years. The median follow-up length was 2.90 years. The Rutherford categories I, IIa, IIb, and III included 1, 38, 51, and 3 cases, respectively. Thromboembolectomy was performed in all patients in the embolism and thrombosis groups. In addition, endovascular treatment was performed in 25 (37.3%) patients, especially in the thrombosis group (81.3%). A major amputation could not be avoided in 10 patients. The 5-year limb salvage rates for categories IIa and IIb were 97.1% and 83.1%, respectively. The 5-year freedom from re-intervention rate was 89.2%. The survival rates at 1, 3, and 5 years were 87.9%, 75.2%, and 60.6%, respectively. Conclusion: The 5-year survival rates of patients with ALI were equivalent to those with chronic limb threatening ischemia (CLTI). The intervention and long-term outcomes were distinguishable according to etiology.

  45. 感染性腹部大動脈瘤に対する解剖学的血行再建の手術成績 Peer-reviewed

    橋本 宗敬, 後藤 均, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太, 梅津 道久, 鈴木 峻也, 亀井 尚

    日本血管外科学会雑誌　28　(1)　35-40　2019/02

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  46. Oral Steroid Use and Abdominal Aortic Aneurysm Expansion - Positive Association Peer-reviewed

    Yuta Tajima, Hitoshi Goto, Masato Ohara, Munetaka Hashimoto, Daijiro Akamatsu, Takuya Shimizu, Noriyuki Miyama, Ken Tsuchida, Keiichiro Kawamura, Michihisa Umetsu, Shunya Suzuki, Noriaki Ohuchi

    CIRCULATION JOURNAL　81　(12)　1774-+　2017/12

    DOI： 10.1253/circj.CJ-16-0902 　

    ISSN： 1346-9843

    eISSN： 1347-4820

  47. Natural History and Chronological Growth Rate of Renal Artery Aneurysms. Peer-reviewed

    Umetsu M, Goto H, Ohara M, Hashimoto M, Shimizu T, Akamatsu D, Tsuchida K, Tajima Y, Suzuki S, Yamamoto K, Miyagi S, Unno M, Kamei T

    Annals of vascular diseases　10　(4)　411-416　2017/12

    DOI： 10.3400/avd.oa.17-00075 　

    ISSN： 1881-641X

  48. ハイブリッド手術を行った上腸間膜動脈閉塞を伴う多発膵十二指腸動脈瘤の1例 Peer-reviewed

    清水拓也, 後藤均, 橋本宗敬, 赤松大二朗, 土田憲, 河村圭一郎, 田島悠太, 梅津道久, 亀井尚

    血管外科　36　(1)　64‐69-69　2017/11/25

    Publisher: 血管外科症例検討会

  49. Efficacy of iliac inflow repair in patients with concomitant iliac and superficial femoral artery occlusive disease Peer-reviewed

    Daijirou Akamatsu, Hitoshi Goto, Takashi Kamei, Shigehito Miyagi, Ken Tsuchida, Keiichiro Kawamura, Yuta Tajima, Michihisa Umetsu, Tetsuo Watanabe, Noriaki Ohuchi

    Asian Journal of Surgery　40　(6)　475-480　2017/11/01

    DOI： 10.1016/j.asjsur.2016.07.004 　

    ISSN： 0219-3108 1015-9584

  50. Histological Analysis of a New Route after Subintimal Crural Angioplasty Peer-reviewed

    Daijirou Akamatsu, Fumiyoshi Fujishima, Hitoshi Goto, Munetaka Hashimoto, Ken Tsuchida, Keiichirou Kawamura, Yuta Tajima, Michihisa Umetsu, Syunya Suzuki, Takashi Kamei

    ANNALS OF VASCULAR SURGERY　45　262.e15-262.e19　2017/11

    DOI： 10.1016/j.avsg.2017.06.038 　

    ISSN： 0890-5096

    eISSN： 1615-5947

  51. 空腸挙上による腸管再建を行った二次性腹部大動脈十二指腸瘻の1例 Peer-reviewed

    橋本 宗敬, 後藤 均, 大原 勝人, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太, 梅津 道久, 大内 憲明

    血管外科　35　(1)　79-84　2016/11

    Publisher: 血管外科症例検討会

  52. Long-Term Outcomes of Surgical Treatment with In Situ Graft Reconstruction for Secondary Aorto-Enteric Fistula. Peer-reviewed

    Hashimoto M, Goto H, Akamatsu D, Shimizu T, Tsuchida K, Kawamura K, Tajima Y, Umetsu M

    Annals of vascular diseases　9　(3)　173-179　2016

    DOI： 10.3400/avd.oa.16-00082 　

    ISSN： 1881-641X

    More details Close

    Objectives: The optimal surgical management for secondary aorto-enteric fistula (sAEF) is controversial. Here, we report the long-term outcomes of a surgical treatment with in situ graft reconstruction for sAEF that was performed at our hospital. Methods: Between 2009 and 2012, 10 consecutive patients (8 males, 2 females, mean age 75.9 years) with sAEF were surgically treated with in situ graft reconstruction. Perioperative and long-term outcomes were reviewed retrospectively by medical records. Results: Clinical manifestations, including gastrointestinal bleeding, shock, sepsis, and back and abdominal pain, were observed during the treatment of the patients. In all the cases, the fistula was found between the duodenum or small intestine and the graft anastomosis, the graft itself, or pseudoaneurysm. Total graft excision and in situ graft reconstruction with omental coverage and digestive tract reconstruction was performed for all cases. There were two operative deaths because of multiple organ dysfunction syndrome and sepsis. The other patients showed no sAEF related complications, such as graft infection, and were alive during the 54-month mean follow-up period (33-76 months). Conclusion: According to our study, the long-term outcomes of surgical treatment with in situ graft reconstruction for sAEF were considered satisfactory. (This article is a translation of Jpn J Vasc Surg 2016; 25: 1-6.).

  53. 両側性膝窩動脈捕捉症候群の2例 Peer-reviewed

    梅津道久, 後藤均, 橋本宗敬, 赤松大二朗, 清水拓也, 土田憲, 河村圭一郎, 田島悠太, 大内憲明

    血管外科　34　(1)　68‐73-73　2015/11/25

    Publisher: 血管外科症例検討会

  54. Transdermal Glyceryl Trinitrate Administration to the Limb of Peripheral Artery Disease Improves Intermittent Claudication Peer-reviewed

    Tsuchida Ken, Goto Hitoshi, Hashimoto Munetaka, Akamatsu Daijirou, Shimizu Takuya, Kawamura Keiichirou, Tajima Yuta, Umetsu Michihisa, Ohuchi Noriaki

    The Journal of Japanese College of Angiology　55　(10)　179-184　2015/11

    Publisher: 日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  55. Long-term Outcomes of Surgical Treatment with In situ Graft Reconstruction for Secondary Aorto-enteric Fistula Peer-reviewed

    Hashimoto Munetaka, Goto Hitoshi, Akamatsu Daijirou, Shimizu Takuya, Tsuchida Ken, Kawamura Keiichiro, Tajima Yuta, Umetsu Michihisa

    Japanese Journal of Vascular Surgery　25　(0)　1-6　2015

    Publisher: 特定非営利活動法人 日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

Show all ︎Show first 5

Misc. 118

  1. 遠隔期を見据えた腹部大動脈瘤の治療選択(腹部大動脈瘤の外科治療) 術式の利点を活かし遠隔期成績を見据えた腹部大動脈瘤治療戦略

    梅津 道久, 赤松 大二朗, 芹澤 玄, 鈴木 峻也, 高橋 宏和, 木村 俊作, 清水 港太, 村上 皓彦, 宮田 惟, 亀井 尚

    脈管学　64　(Suppl.)　S110-S111　2024/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  2. 腹部大動脈瘤患者における腸内細菌叢の網羅的検索

    清水 港太, 赤松 大二朗, 芹澤 玄, 梅津 道久, 鈴木 峻也, 高橋 宏和, 木村 俊作, 村上 皓彦, 宮田 惟

    脈管学　64　(Suppl.)　S148-S148　2024/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  3. 内腸骨動脈塞栓・結紮が日常歩行へ与える影響

    木村 俊作, 赤松 大二朗, 芹澤 玄, 梅津 道久, 鈴木 峻也, 高橋 宏和, 清水 港太, 宮田 惟, 村上 皓彦, 亀井 尚

    脈管学　64　(Suppl.)　S151-S151　2024/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  4. 下肢静脈瘤血管内治療の有害事象:重大合併症は本当に多いのか? 下肢静脈瘤に対するシアノアクリレート系接着材による血管内治療の合併症に関する緊急調査 第二弾調査報告

    梅津 道久, 広川 雅之, 手島 英一, 深谷 絵里, 草川 均, 西部 俊哉, 孟 真, 小川 智弘

    静脈学　35　(2)　216-216　2024/05

    Publisher: (一社)日本静脈学会

    ISSN： 0915-7395

    eISSN： 2186-5523

  5. 下肢静脈瘤血管内治療の有害事象:重大合併症は本当に多いのか? シアノアクリレート系接着材による血管内治療の合併症に関する緊急調査,Phlebitisについて

    手島 英一, 広川 雅之, 梅津 道久, 深谷 絵里, 草川 均, 西部 俊哉, 孟 真, 小川 智弘

    静脈学　35　(2)　216-216　2024/05

    Publisher: (一社)日本静脈学会

    ISSN： 0915-7395

    eISSN： 2186-5523

  6. 【サーベイ委員会報告】一次性下肢静脈瘤治療に関するアンケート調査

    田淵 篤, 八巻 隆, 佐戸川 弘之, 白石 恭史, 西部 俊哉, 野村 正, 松本 崇, 山田 典一, 山下 侑吾, 根本 寛子, 梅津 道久, 孟 真, 日本静脈学会静脈疾患サーベイ委員会

    静脈学　35　(2)　225-225　2024/05

    Publisher: (一社)日本静脈学会

    ISSN： 0915-7395

    eISSN： 2186-5523

  7. Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Symptom: ONCO DVT Study(タイトル和訳中)

    荻原 義人, 山下 侑吾, 村岡 直穂, 梅津 道久, 西本 裕二, 高田 卓磨, 西川 達哉, 池田 長生, 乙井 一典, 末田 大輔, 津端 由佳里, 庄司 正昭, 志鎌 あゆみ, 細井 温, 田邉 康宏, 茶谷 龍己, 塚原 健吾, 中西 直彦, 佐藤 徹, 土肥 薫

    日本循環器学会学術集会抄録集　88回　OJ14-8　2024/03

    Publisher: (一社)日本循環器学会

  8. EVARにおけるTypeII endoleak-だからどうするべき?今日決着! 予防塞栓を行わない施設データから考える予防塞栓の効果

    芹澤 玄, 赤松 大二朗, 大原 勝人, 梅津 道久, 鈴木 峻也, 高橋 宏和, 清水 港太, 木村 俊作, 村上 皓彦, 宮田 惟, 亀井 尚

    日本血管外科学会雑誌　33　(Suppl.)　SY5-3　2024

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  9. 腹部大動脈瘤治療の長期成績へのアプローチ 待機手術における治療戦略の検証

    梅津 道久, 赤松 大二朗, 芹澤 玄, 鈴木 峻也, 高橋 宏和, 木村 俊作, 清水 港太, 村上 皓彦, 宮田 唯, 小坂 淳生

    日本血管外科学会雑誌　33　(Suppl.)　O14-5　2024

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  10. Diagnosis of acute limb ischemia and mesenteric ischemia

    赤松大二朗, 芹澤玄, 梅津道久, 鈴木峻也, 亀井尚

    日本臨床　82　(増刊4 動脈・静脈の疾患2024(上))　277-282　2024

    Publisher: (株)日本臨床社

    ISSN： 0047-1852

  11. 膵頭十二指腸切除後創し開・腸管皮膚瘻に対して長期間保存的加療を行った後に外科的閉鎖術を施行した一例

    伊関 雅裕, 中川 圭, 水間 正道, 堂地 大輔, 三浦 孝之, 前田 晋平, 石田 晶玄, 大塚 英郎, 鈴木 綾乃, 黒沢 是之, 今井 啓道, 梅津 道久, 赤松 大二朗, 亀井 尚, 海野 倫明

    日本外科感染症学会雑誌　20　(3)　448-448　2023/11

    Publisher: (一社)日本外科感染症学会

    ISSN： 1349-5755

    eISSN： 2434-0103

  12. 化学療法センターにおける深部静脈血栓症

    梅津 道久, 赤松 大二朗, 芹澤 玄, 鈴木 峻也, 高橋 宏和, 木村 俊作, 清水 港太, 村上 皓彦, 亀井 尚

    脈管学　63　(Suppl.)　S172-S172　2023/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  13. 感染性腹部大動脈瘤の周術期に副腎不全を合併した一例

    村上 皓彦, 赤松 大二朗, 吉田 良太朗, 芹澤 玄, 梅津 道久, 鈴木 峻也, 木村 俊作, 清水 港太

    脈管学　63　(Suppl.)　S231-S232　2023/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  14. persistent type2エンドリークに対する対策 瘤径拡大を基準としたType 2エンドリーク症例への介入は必要か

    芹澤 玄, 赤松 大二朗, 梅津 道久, 鈴木 峻也, 清水 港太, 木村 俊作, 村上 皓彦, 海野 倫明, 亀井 尚

    脈管学　63　(Suppl.)　S111-S112　2023/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  15. 感染性腹部大動脈瘤の周術期に副腎不全を合併した一例

    村上 皓彦, 赤松 大二朗, 吉田 良太朗, 芹澤 玄, 梅津 道久, 鈴木 峻也, 木村 俊作, 清水 港太

    脈管学　63　(Suppl.)　S231-S232　2023/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  16. 破裂性腹部大動脈瘤に対する初期治療戦略と周術期管理

    木村 俊作, 赤松 大二朗, 芹澤 玄, 梅津 道久, 鈴木 峻也, 高橋 宏和, 小笠原 紀信, 清水 港太, 石田 孝宣, 亀井 尚

    日本外科系連合学会誌　48　(3)　401-401　2023/05

    Publisher: 日本外科系連合学会

    ISSN： 0385-7883

    eISSN： 1882-9112

  17. CLTI(包括的高度慢性下肢虚血)の治療選択 Distal Bypass術後のSPP連続測定から考えるDirect Revascularizationの意義

    芹澤 玄, 中野 善之, 佐々木 茂, 佐藤 博子, 橋本 宗敬, 玉手 義久, 鈴木 峻也, 大原 勝人, 河村 圭一郎, 渡辺 徹雄, 梅津 道久, 小笠原 紀信, 清水 港太, 木村 俊作, 赤松 大二朗, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　123回　WS-7　2023/04

    Publisher: (一社)日本外科学会

  18. COVID-19感染症関連血栓症の分析 CLOT-COVID studyの総括(2)

    中田 弘子, 山本 尚人, 梅津 道久, 相川 志都, 佐戸川 弘之, 岩田 英理子, 岩井 武久, 小川 智弘, 小林 隆夫, 孟 真, 山下 侑吾

    日本血管外科学会雑誌　32　(Suppl.)　SP4-2　2023

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  19. 新型コロナウイルス感染症(COVID-19)における血栓症予防および抗凝固療法の診療指針(Ver4.1)

    孟 真, 梅津 道久, 中田 弘子, 山下 侑吾, 山本 尚人, 相川 志都, 佐戸川 弘之, 岩田 英理子, 小川 智弘, 小林 隆夫, 岩井 武尚

    日本血管外科学会雑誌　32　(Suppl.)　SP4-3　2023

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  20. 他科手術と血管外科の関わり(腫瘍外科時の血行再建、Rescue Surgeryなど) 根治的腫瘍切除を目指した下大静脈合併切除についての検討

    鈴木 峻也, 赤松 大二朗, 芹澤 玄, 梅津 道久, 小笠原 紀信, 高橋 宏和, 木村 俊作, 清水 港太, 石田 孝宣, 海野 倫明, 亀井 尚

    日本血管外科学会雑誌　32　(Suppl.)　VS1-7　2023

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  21. 感染性大動脈瘤に対する治療戦略(グラフト感染、大動脈-食道・十二指腸瘻を含む) 感染性腹部大動脈疾患に対するリファンピシン浸漬人工血管を用いたIn-Situ再建・大網被覆術の中期成績

    赤松 大二朗, 芹澤 玄, 梅津 道久, 鈴木 峻也, 小笠原 紀信, 木村 俊作, 清水 港太

    日本血管外科学会雑誌　32　(Suppl.)　PD4-2　2023

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  22. 血管型エーラス・ダンロス症候群患者8例の臨床経過と血管内治療

    小笠原 紀信, 赤松 大二朗, 芹澤 玄, 梅津 道久, 鈴木 峻也, 高橋 宏和, 木村 俊作, 清水 港太, 大沼 忍, 石田 孝宜, 海野 倫明, 亀井 尚

    日本血管外科学会雑誌　32　(Suppl.)　RO4-3　2023

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  23. 脾動脈瘤における外来経過観察の間隔と治療介入の時期の検討

    清水 港太, 赤松 大二朗, 芹澤 玄, 梅津 道久, 鈴木 峻也, 小笠原 紀信, 高橋 宏和, 木村 俊作, 亀井 尚

    日本血管外科学会雑誌　32　(Suppl.)　RO11-2　2023

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  24. Type 2 Endoleakを伴う瘤径拡大症例の治療適応に関する検討

    芹澤 玄, 清水 港太, 木村 俊作, 小笠原 紀信, 高橋 宏和, 鈴木 俊也, 梅津 道久, 赤松 大二朗, 海野 倫明, 亀井 尚

    日本血管外科学会雑誌　32　(Suppl.)　O14-4　2023

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  25. 上腕動脈の塞栓閉塞を伴う動脈性胸郭出口症候群の1例

    小笠原 紀信, 赤松 大二朗, 芹澤 玄, 梅津 道久, 鈴木 峻也, 高橋 宏和, 木村 俊作, 清水 港太, 相澤 俊峰, 大沼 忍, 石田 孝宜, 海野 倫明, 亀井 尚

    血管外科　41　(1)　72-78　2022/11

    Publisher: 血管外科症例検討会

  26. 脈管疾患における抗凝固療法の進歩 COVID-19と抗凝固療法 日本での新型コロナウイルス感染症と静脈血栓塞栓症 タスクフォース実態調査報告を含めて

    孟 真, 山下 侑吾, 小林 隆夫, 小川 智弘, 山田 典一, 中田 弘子, 佐戸川 弘之, 池田 聡司, 山本 尚人, 谷地 繊, 竹山 誠, 西本 裕二, 林 浩也, 中村 順一, 辻野 一三, 梅津 道久, 荻原 義人, 池田 長生, 相川 志都, 岩田 英理子

    脈管学　62　(Suppl.)　S106-S106　2022/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  27. 当科における急性下肢虚血の治療成績

    鈴木 峻也, 赤松 大二朗, 芹澤 玄, 梅津 道久, 小笠原 紀信, 木村 俊作, 清水 港太, 亀井 尚

    脈管学　62　(Suppl.)　S139-S139　2022/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  28. COVID-19と血栓症 総論、海外と我が国のデータ

    谷地 繊, 竹山 誠, 山下 侑吾, 西本 裕二, 辻野 一三, 中村 順一, 山本 尚人, 中田 弘子, 池田 聡司, 梅津 道久, 相川 志都, 林 浩也, 佐戸川 弘, 奥野 善教, 岩田 英理子, 荻原 義人, 池田 長生, 近藤 朱音, 岩井 武尚, 山田 典一, 小川 智弘, 小林 隆夫, 孟 真

    静脈学　33　(2)　144-144　2022/06

    Publisher: (一社)日本静脈学会

    ISSN： 0915-7395

    eISSN： 2186-5523

  29. COVID-19患者における入院時D-ダイマーの重要性

    池田 長生, 谷地 繊, 竹山 誠, 西本 裕二, 辻野 一三, 中村 順一, 山本 尚人, 中田 弘子, 池田 聡司, 梅津 道久, 相川 志都, 林 浩也, 佐戸川 弘, 奥野 善教, 岩田 英理子, 荻原 義人, 近藤 朱音, 岩井 武尚, 山田 典一, 小川 智弘, 小林 隆夫, 孟 真, 山下 侑吾

    静脈学　33　(2)　148-148　2022/06

    Publisher: (一社)日本静脈学会

    ISSN： 0915-7395

    eISSN： 2186-5523

  30. 大動脈気管支瘻腸管瘻に対する治療 一期的開腹手術による二次性腹部大動脈腸管瘻(sAEF)に対する治療成績

    赤松 大二朗, 後藤 均, 橋本 宗敬, 芹澤 玄人, 田島 悠太, 梅津 道久, 堀井 晋一良, 高橋 宏和, 小笠原 紀信, 長岡 洋平, 清水 港太, 木村 俊作, 大沼 忍, 石田 孝宣, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　122回　WS-4　2022/04

    Publisher: (一社)日本外科学会

  31. 大動脈気管支瘻腸管瘻に対する治療 一期的開腹手術による二次性腹部大動脈腸管瘻(sAEF)に対する治療成績

    赤松 大二朗, 後藤 均, 橋本 宗敬, 芹澤 玄人, 田島 悠太, 梅津 道久, 堀井 晋一良, 高橋 宏和, 小笠原 紀信, 長岡 洋平, 清水 港太, 木村 俊作, 大沼 忍, 石田 孝宣, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　122回　WS-4　2022/04

    Publisher: (一社)日本外科学会

  32. 感染を伴った腹部大動脈・腹部動脈の手術 腹部大動脈感染性疾患に対するin-situ人工血管再建・大網被覆術

    赤松 大二朗, 後藤 均, 芹澤 玄, 田島 悠太, 梅津 道久, 小笠原 紀信, 高橋 宏和, 亀井 尚

    日本血管外科学会雑誌　31　(Suppl.)　SY1-1　2022

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  33. 間歇性跛行を呈するAortoiliac Occlusive disease患者に対する血管内治療後の歩行の変化 三次元動作解析を用いた検討

    小笠原 紀信, 赤松 大二朗, 芹澤 玄, 田島 悠太, 梅津 道久, 堀井 晋一良, 高橋 宏和, 長岡 洋平, 石田 孝宜, 海野 倫明, 亀井 尚

    日本血管外科学会雑誌　31　(Suppl.)　P33-1　2022

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  34. 腹部大動脈ステントグラフト内挿術後の遠隔期におけるType 2 endoleakに対する動脈塞栓術の有効性の検討

    長岡 洋平, 芹澤 玄, 小笠原 紀信, 高橋 宏和, 堀井 晋一良, 梅津 道久, 田島 悠太, 赤松 大二朗

    脈管学　61　(Suppl.)　S153-S153　2021/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  35. 内腸骨動脈塞栓を伴うステントグラフト内挿術後に合併する臀筋跛行の予後

    鈴木 峻也, 赤松 大二朗, 後藤 均, 柿花 隆明, 菅原 宏文, 土田 憲, 吉田 良太朗, 田島 悠太, 梅津 道久, 堀井 晋一良, 高橋 宏和, 小笠原 紀信, 長岡 洋平, 亀井 尚

    日本外科学会定期学術集会抄録集　121回　PS-3　2021/04

    Publisher: (一社)日本外科学会

  36. 内腸骨動脈塞栓を伴うステントグラフト内挿術後の臀筋跛行における前向き調査

    鈴木 峻也, 赤松 大二朗, 後藤 均, 柿花 隆明, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 堀井 晋一良, 亀井 尚

    日本血管外科学会雑誌　30　(Suppl.)　PR8-1　2021

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  37. 腹部大動脈瘤に対するステントグラフト内挿術時の出血量の検討

    高橋 宏和, 芹澤 玄, 長岡 洋平, 小笠原 紀信, 堀井 晋一良, 鈴木 峻也, 梅津 道久, 吉田 良太朗, 土田 憲, 菅原 宏文, 赤松 大二朗, 後藤 均, 亀井 尚

    日本血管外科学会雑誌　30　(Suppl.)　O35-3　2021

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  38. 当院における腎動脈瘤に対するex vivo surgeryの検討

    土田 憲, 後藤 均, 赤松 大二朗, 菅原 宏文, 吉田 良太朗, 鈴木 峻也, 堀井 晋一良, 小笠原 紀信, 高橋 宏和, 亀井 尚, 海野 倫明, 梅津 道久

    日本血管外科学会雑誌　29　(Suppl.)　OP31-2　2020

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  39. Efficacy of Endovascular Therapy in Gait Kinetics of Patients with Peripheral Arterial Disease with Intermittent Claudication

    Takaaki Kakihana, Hitoshi Goto, Daijirou Akamatsu, Yusuke Sekiguchi, Mina Akizuki, Hirofumi Sugawara, Ken Tsuchida, Michihisa Umetsu, Shunya Suzuki, Osamu Ito, Masahiro Kohzuki

    European Journal of Vascular and Endovascular Surgery　58　(6(Suppl.3))　e425-e425　2019/12

  40. Study on Prognosis of Buttock Claudication in Endovascular Aneurysm Repair Cases Involving Internal Iliac Artery Embolization−comparison of Bilateral and Unilateral Embolization

    Shunya Suzuki, Hitoshi Goto, Daijirou Akamatsu, Hirofumi Sugawara, Ken Tsuchida, Yoshitarou Yoshida, Michihisa Umetsu, Shinichirou Horii, Norinobu Ogasawara, Hirokazu Takahashi

    European Journal of Vascular and Endovascular Surgery　58　(6(Suppl.3))　e793-e794　2019/12

  41. 症候性上腸間膜動脈解離症例の検討

    菅原 宏文, 後藤 均, 赤松 大二朗, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 小笠原 紀信, 高橋 宏和, 海野 倫明, 亀井 尚

    脈管学　59　(Suppl.)　S190-S190　2019/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  42. 当科で経験した感染性末梢動脈瘤12例の検討

    高橋 宏和, 小笠原 紀信, 堀井 晋一良, 鈴木 峻也, 梅津 道久, 吉田 良太朗, 土田 憲, 菅原 宏文, 赤松 大二朗, 後藤 均

    脈管学　59　(Suppl.)　S229-S229　2019/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  43. 総大腿動脈(CFA)病変に対する、血栓内膜摘除術の手術成績の検討

    小笠原 紀信, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 高橋 宏和, 内藤 剛, 海野 倫明, 石田 孝宣, 亀井 尚

    脈管学　59　(Suppl.)　S238-S239　2019/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  44. 進行腎細胞癌による下肢動脈腫瘍塞栓の一例

    鈴木 峻也, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 堀井 晋一良, 小笠原 紀信, 高橋 宏和, 亀井 尚, 海野 倫明, 石田 孝宣, 内藤 剛

    脈管学　59　(Suppl.)　S277-S277　2019/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  45. 【肝胆膵の救急疾患とその最新の治療現場】古典的な肝胆膵での救急疾患とその最新治療 上腸間膜動脈閉塞・解離に対するアプローチ

    菅原 宏文, 後藤 均, 赤松 大二朗, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 海野 倫明, 亀井 尚

    肝・胆・膵　79　(4)　651-658　2019/10

    Publisher: (株)アークメディア

    ISSN： 0389-4991

  46. CAT:cancer associated thrombosisに対する治療戦略 がん関連血栓症として発症した静脈血栓塞栓症に対するwarfarinとDOACの比較検討

    後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 高橋 宏和, 小笠原 紀信, 亀井 尚

    脈管学　59　(Suppl.)　S131-S131　2019/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  47. 症候性上腸間膜動脈解離症例の検討

    菅原 宏文, 後藤 均, 赤松 大二朗, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 小笠原 紀信, 高橋 宏和, 海野 倫明, 亀井 尚

    脈管学　59　(Suppl.)　S190-S190　2019/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  48. 当科で経験した感染性末梢動脈瘤12例の検討

    高橋 宏和, 小笠原 紀信, 堀井 晋一良, 鈴木 峻也, 梅津 道久, 吉田 良太朗, 土田 憲, 菅原 宏文, 赤松 大二朗, 後藤 均

    脈管学　59　(Suppl.)　S229-S229　2019/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  49. 総大腿動脈(CFA)病変に対する、血栓内膜摘除術の手術成績の検討

    小笠原 紀信, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 高橋 宏和, 内藤 剛, 海野 倫明, 石田 孝宣, 亀井 尚

    脈管学　59　(Suppl.)　S238-S239　2019/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  50. 進行腎細胞癌による下肢動脈腫瘍塞栓の一例

    鈴木 峻也, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 堀井 晋一良, 小笠原 紀信, 高橋 宏和, 亀井 尚, 海野 倫明, 石田 孝宣, 内藤 剛

    脈管学　59　(Suppl.)　S277-S277　2019/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  51. 超常磁性酸化鉄造影剤を用いた核磁気共鳴画像法による腹部大動脈瘤の中膜および外膜内の組織マクロファージの局在評価

    梅津 道久, 後藤 均, 赤松 大二朗, 菅原 宏文, 濱田 庸, 土田 憲, 吉田 良太朗, 鈴木 峻也, 堀井 晋一良, 内藤 剛, 石田 孝宜, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　119回　PS-148　2019/04

    Publisher: (一社)日本外科学会

  52. 超常磁性酸化鉄造影剤を用いた核磁気共鳴画像法による腹部大動脈瘤の中膜および外膜内の組織マクロファージの局在評価

    梅津 道久, 後藤 均, 赤松 大二朗, 菅原 宏文, 濱田 庸, 土田 憲, 吉田 良太朗, 鈴木 峻也, 堀井 晋一良, 内藤 剛, 石田 孝宜, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　119回　PS-148　2019/04

    Publisher: (一社)日本外科学会

  53. 下腿単独病変による重症虚血肢における治療の課題

    赤松 大二朗, 後藤 均, 菅原 宏文, 濱田 庸, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 内藤 剛, 海野 倫明, 石田 孝宣, 亀井 尚

    日本外科学会定期学術集会抄録集　119回　SF-042　2019/04

    Publisher: (一社)日本外科学会

  54. 非解剖学的上腸間膜バイパスを施行した13例の検討

    濱田 庸, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 海野 倫明, 内藤 剛, 石田 孝宣, 亀井 尚

    日本外科学会定期学術集会抄録集　119回　PS-144　2019/04

    Publisher: (一社)日本外科学会

  55. 下腿単独病変による重症虚血肢における治療の課題

    赤松 大二朗, 後藤 均, 菅原 宏文, 濱田 庸, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 内藤 剛, 海野 倫明, 石田 孝宣, 亀井 尚

    日本外科学会定期学術集会抄録集　119回　SF-042　2019/04

    Publisher: (一社)日本外科学会

  56. 非解剖学的上腸間膜バイパスを施行した13例の検討

    濱田 庸, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 海野 倫明, 内藤 剛, 石田 孝宣, 亀井 尚

    日本外科学会定期学術集会抄録集　119回　PS-144　2019/04

    Publisher: (一社)日本外科学会

  57. 感染性腹部大動脈瘤に対する解剖学的血行再建の手術成績

    橋本 宗敬, 後藤 均, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太, 梅津 道久, 鈴木 峻也, 亀井 尚

    日本血管外科学会雑誌　28　(1)　35-40　2019/02

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  58. 多領域に血栓が充満したVTEに対する血管内治療の役割

    梅津 道久, 後藤 均, 赤松 大二朗, 菅原 宏文, 濱田 庸, 土田 憲, 吉田 良太朗, 鈴木 峻也, 堀井 晋一良, 小笠原 紀信, 海野 倫明, 亀井 尚

    日本血管外科学会雑誌　28　(Suppl.)　O9-4　2019

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  59. 腹部内臓動脈へのDebranchingを併用したステントグラフト治療の報告

    鈴木 峻也, 後藤 均, 赤松 大二朗, 菅原 宏文, 濱田 庸, 土田 憲, 吉田 良太朗, 梅津 道久, 堀井 晋一良

    日本血管外科学会雑誌　28　(Suppl.)　P15-4　2019

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  60. 長時間腎動脈遮断を要した腹部大動脈瘤手術症例における冷却リンゲル液自然滴下灌流による腎保護効果の検討

    堀井晋一良, 菅原宏文, 梅津道久, 海野倫明, 亀井尚

    日本臨床外科学会雑誌　79　401　2018/10/20

    ISSN： 1345-2843

  61. 破裂性腹部大動脈瘤に対する開腹手術とステントグラフト内挿術の検討

    土田 憲, 後藤 均, 赤松 大二朗, 菅原 宏文, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 亀井 尚, 海野 倫明

    Japanese Journal of Acute Care Surgery　8　(1)　98-98　2018/09

    Publisher: 日本Acute Care Surgery学会

  62. 血管外科手術の巧み

    後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 亀井 尚, 海野 倫明

    Japanese Journal of Acute Care Surgery　8　(1)　42-42　2018/09

    Publisher: 日本Acute Care Surgery学会

  63. 血管機能検査によるPADの評価

    鈴木 峻也, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 堀井 晋一良

    脈管学　58　(Suppl.)　S164-S165　2018/09

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

  64. 腎動脈上遮断を要する腹部大動脈瘤手術症例に対する冷却リンゲル液自然滴下灌流による腎保護効果の検討

    堀井 晋一良, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 海野 倫明, 亀井 尚

    脈管学　58　(Suppl.)　S174-S174　2018/09

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

  65. 血管機能検査によるPADの評価

    鈴木 峻也, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 堀井 晋一良

    脈管学　58　(Suppl.)　S164-S165　2018/09

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

  66. 腎動脈上遮断を要する腹部大動脈瘤手術症例に対する冷却リンゲル液自然滴下灌流による腎保護効果の検討

    堀井 晋一良, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 海野 倫明, 亀井 尚

    脈管学　58　(Suppl.)　S174-S174　2018/09

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

  67. 血管外科手術の巧み

    後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 亀井 尚, 海野 倫明

    Japanese Journal of Acute Care Surgery　8　(1)　42-42　2018/09

    Publisher: 日本Acute Care Surgery学会

  68. 破裂性腹部大動脈瘤に対する開腹手術とステントグラフト内挿術の検討

    土田 憲, 後藤 均, 赤松 大二朗, 菅原 宏文, 吉田 良太朗, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 亀井 尚, 海野 倫明

    Japanese Journal of Acute Care Surgery　8　(1)　98-98　2018/09

    Publisher: 日本Acute Care Surgery学会

  69. 血行再建後のリハビリテーションはどうあるべきか 血行再建術は間歇性跛行を呈する末梢動脈疾患患者の歩き方を変化させるか?

    柿花 隆昭, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 梅津 道久, 鈴木 峻也, 関口 雄介, 秋月 三奈, 伊藤 修, 上月 正博

    日本下肢救済・足病学会誌　10　(2)　133-133　2018/07

    Publisher: 日本下肢救済・足病学会

    ISSN： 1883-857X

  70. 血行再建後のリハビリテーションはどうあるべきか 血行再建術は間歇性跛行を呈する末梢動脈疾患患者の歩き方を変化させるか?

    柿花 隆昭, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 梅津 道久, 鈴木 峻也, 関口 雄介, 秋月 三奈, 伊藤 修, 上月 正博

    日本下肢救済・足病学会誌　10　(2)　133-133　2018/07

    Publisher: 日本下肢救済・足病学会

    ISSN： 1883-857X

    eISSN： 2187-1957

  71. 担癌患者に対するVTE治療の変遷

    梅津道久, 後藤均, 橋本宗敬, 赤松大二朗, 菅原宏文, 土田憲, 鈴木峻也, 亀井尚

    日本血管外科学会雑誌(Web)　27　(Supplement)　ROMBUNNO.P17‐5(J‐STAGE)-5　2018/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 1881-767X

  72. 担癌患者に対するVTE治療の変遷

    梅津 道久, 後藤 均, 橋本 宗敬, 赤松 大二朗, 菅原 宏文, 土田 憲, 鈴木 峻也, 亀井 尚

    日本血管外科学会雑誌　27　(Suppl.)　P17-5　2018/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  73. EVARにおける内腸骨動脈塞栓症例の検討

    後藤 均, 佐藤 博子, 鈴木 峻也, 橋本 宗敬, 赤松 大二朗, 菅原 宏文, 土田 憲, 梅津 道久, 亀井 尚

    日本血管外科学会雑誌　27　(Suppl.)　SS(M)2 keynote-SS(M)2 keynote　2018/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  74. 感染性腹部大動脈瘤に対する手術成績

    橋本 宗敬, 後藤 均, 赤松 大二朗, 菅原 宏文, 土田 憲, 梅津 道久, 鈴木 峻也

    日本血管外科学会雑誌　27　(Suppl.)　P8-10　2018/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  75. 当院における重症下肢虚血患者治療後の機能予後

    菅原 宏文, 後藤 均, 橋本 宗敬, 赤松 大二朗, 土田 憲, 梅津 道久, 鈴木 峻也, 亀井 尚

    日本血管外科学会雑誌　27　(Suppl.)　P33-5　2018/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  76. 下腿単独病変による重症虚血肢に対する血行再建の治療戦略とエビデンス 下腿単独病変によるCLIに対する血行再建術式の選択

    赤松 大二朗, 後藤 均, 橋本 宗敬, 菅原 宏文, 土田 憲, 梅津 道久, 鈴木 峻也, 堀井 晋一良, 亀井 尚

    日本血管外科学会雑誌　27　(Suppl.)　S5 keynote-S5 keynote　2018/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  77. CLI治療後の機能予後-血行再建は歩行機能、QOLにどれだけ寄与しているか- 間歇性跛行を呈する末梢動脈疾患患者における血行再建術前後の歩行解析 三次元動作解析を用いた検討

    柿花 隆昭, 伊藤 修, 後藤 均, 橋本 宗敬, 赤松 大二朗, 菅原 宏文, 土田 憲, 梅津 道久, 鈴木 峻也, 関口 雄介, 秋月 三奈, 上月 正博

    日本血管外科学会雑誌　27　(Suppl.)　PD4-2　2018/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  78. 感染性腹部大動脈瘤に対する手術成績

    橋本宗敬, 後藤均, 赤松大二朗, 菅原宏文, 土田憲, 梅津道久, 鈴木峻也

    日本血管外科学会雑誌(Web)　27　(Supplement)　ROMBUNNO.P8‐10(J‐STAGE)-10　2018/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 1881-767X

  79. 当院における重症下肢虚血患者治療後の機能予後

    菅原宏文, 後藤均, 橋本宗敬, 赤松大二朗, 土田憲, 梅津道久, 鈴木峻也, 亀井尚

    日本血管外科学会雑誌(Web)　27　(Supplement)　ROMBUNNO.P33‐5(J‐STAGE)-5　2018/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 1881-767X

  80. EVARにおける内腸骨動脈塞栓症例の検討

    後藤均, 佐藤博子, 鈴木峻也, 橋本宗敬, 赤松大二朗, 菅原宏文, 土田憲, 梅津道久, 亀井尚

    日本血管外科学会雑誌(Web)　27　(Supplement)　ROMBUNNO.SS(M)2(J‐STAGE)-SS(M)2 keynote　2018/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 1881-767X

  81. 血行再建術は間歇性跛行を呈する末梢動脈疾患患者の歩き方を変化させるか?

    柿花隆昭, 柿花隆昭, 後藤均, 赤松大二朗, 菅原宏文, 土田憲, 梅津道久, 鈴木峻也, 関口雄介, 関口雄介, 秋月三奈, 秋月三奈, 伊藤修, 上月正博

    日本下肢救済・足病学会誌(Web)　10　(2)　133　2018

    ISSN： 2187-1957

  82. 下腿単独病変によるCLIに対する血行再建術式の選択

    赤松大二朗, 後藤均, 橋本宗敬, 菅原宏文, 土田憲, 梅津道久, 鈴木峻也, 堀井晋一良, 亀井尚

    日本血管外科学会雑誌(Web)　27　(Supplement)　ROMBUNNO.S5(J‐STAGE)　2018

    ISSN： 1881-767X

  83. 間歇性跛行を呈する末梢動脈疾患患者における血行再建術前後の歩行解析―三次元動作解析を用いた検討―

    柿花隆昭, 柿花隆昭, 伊藤修, 後藤均, 橋本宗敬, 赤松大二朗, 菅原宏文, 土田憲, 梅津道久, 鈴木峻也, 関口雄介, 関口雄介, 秋月三奈, 秋月三奈, 上月正博

    日本血管外科学会雑誌(Web)　27　(Supplement)　ROMBUNNO.PD4‐2(J‐STAGE)　2018

    ISSN： 1881-767X

  84. 担癌患者に対する静脈血栓塞栓症治療の選択

    梅津 道久, 後藤 均, 橋本 宗敬, 赤松 大二朗, 土田 憲, 田島 悠太, 鈴木 峻也

    脈管学　57　(Suppl.)　S189-S189　2017/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

  85. PAD患者におけるFMD/NMD検査の有用性の検討

    鈴木 峻也, 赤松 大二朗, 後藤 均, 橋本 宗敬, 土田 憲, 田島 悠太, 梅津 道久

    脈管学　57　(Suppl.)　S160-S160　2017/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

  86. 左内胸動脈を流入血管としたCABG後に生じた左鎖骨下動脈狭窄の一例

    梅津 道久, 後藤 均, 大原 勝人, 橋本 宗敬, 赤松 大二朗, 土田 憲, 田島 悠太, 鈴木 峻也

    日本血管外科学会雑誌　26　(Suppl.)　P32-2　2017/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  87. 多分節病変を有するCLIに対するHybrid手術の治療成績

    赤松 大二朗, 後藤 均, 橋本 宗敬, 土田 憲, 田島 悠太, 梅津 道久, 鈴木 峻也

    日本血管外科学会雑誌　26　(Suppl.)　VS1-6　2017/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  88. 多分節病変を有するCLIに対するHybrid手術の治療成績

    赤松大二朗, 後藤均, 橋本宗敬, 土田憲, 田島悠太, 梅津道久, 鈴木峻也

    日本血管外科学会雑誌(Web)　26　(Supplement)　ROMBUNNO.VS1‐6(J‐STAGE)-6　2017/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 1881-767X

  89. 下腿単独病変による重症虚血肢治療の課題

    赤松 大二朗, 後藤 均, 大原 勝人, 橋本 宗敬, 土田 憲, 田島 悠太, 梅津 道久, 鈴木 峻也, 大内 憲明

    日本外科学会定期学術集会抄録集　117回　SF-10　2017/04

    Publisher: (一社)日本外科学会

  90. 腎動脈瘤におけるMPR再構成を用いた瘤径の経時的変化の検討

    梅津 道久, 後藤 均, 大原 勝人, 橋本 宗敬, 赤松 大二朗, 土田 憲, 田島 悠太

    脈管学　56　(Suppl.)　S177-S177　2016/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

  91. 血管内治療直後における末梢動脈疾患患者の歩行解析

    柿花 隆昭, 伊藤 修, 後藤 均, 大原 勝人, 橋本 宗敬, 赤松 大二朗, 土田 憲, 田島 悠太, 梅津 道久, 関口 雄介, 本田 啓太, 秋月 三奈, 上月 正博

    脈管学　56　(Suppl.)　S180-S180　2016/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

  92. 当院で経験した膠原病に合併した重症虚血肢の検討

    梅津 道久, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太

    日本血管外科学会雑誌　25　(Suppl.)　308-308　2016/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  93. EVARによる治療適応拡大の妥当性について、EVARと開腹手術症例の中長期成績からの検討

    後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太, 梅津 道久, 濱田 庸

    日本血管外科学会雑誌　25　(Suppl.)　171-171　2016/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  94. 血管外科医が行う鼠径以下の血管内治療

    赤松 大二朗, 後藤 均, 橋本 宗敬, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太, 梅津 道久

    日本血管外科学会雑誌　25　(Suppl.)　206-206　2016/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  95. 腹部大動脈瘤の成因と拡大リスク因子に関する前向き観察研究

    田島 悠太, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 深山 紀幸, 濱田 庸, 土田 憲, 河村 圭一郎, 梅津 道久

    日本血管外科学会雑誌　25　(Suppl.)　518-518　2016/06

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

    eISSN： 1881-767X

  96. 悪性腫瘍とVTE 悪性腫瘍に関連するVTEの傾向と対応

    後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太, 梅津 道久

    静脈学　27　(2)　115-115　2016/05

    Publisher: 日本静脈学会

    ISSN： 0915-7395

  97. 当院における急性下肢虚血の検討

    梅津 道久, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太

    日本外科学会定期学術集会抄録集　116回　PS-077　2016/04

    Publisher: (一社)日本外科学会

  98. 血管外科に応援を依頼された他科手術症例の検討

    河村 圭一郎, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 田島 悠太, 梅津 道久, 大内 憲明

    日本外科学会定期学術集会抄録集　116回　PS-157　2016/04

    Publisher: (一社)日本外科学会

  99. Long distal bypassの功罪 バイパス vs カテーテル治療 重症虚血肢に対する血行再建戦略の再考

    赤松 大二朗, 後藤 均, 橋本 宗敬, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太, 梅津 道久, 大内 憲明

    日本外科学会定期学術集会抄録集　116回　WS-19　2016/04

    Publisher: (一社)日本外科学会

  100. 急性発症し長期加療を要した重症虚血肢の1例

    梅津 道久, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太

    日本下肢救済・足病学会誌　8　(1)　100-100　2016/03

    Publisher: 日本下肢救済・足病学会

    ISSN： 1883-857X

  101. EVARによる治療適応拡大の妥当性について,EVARと開腹手術症例の中長期成績からの検討

    後藤均, 橋本宗敬, 赤松大二朗, 清水拓也, 土田憲, 河村圭一郎, 田島悠太, 梅津道久, 濱田庸

    日本血管外科学会雑誌(Web)　25　(Supplement)　171(J‐STAGE)　2016

    ISSN： 1881-767X

  102. 腹部大動脈瘤の成因と拡大リスク因子に関する前向き観察研究

    田島悠太, 後藤均, 橋本宗敬, 赤松大二朗, 清水拓也, 深山紀幸, 濱田庸, 土田憲, 河村圭一郎, 梅津道久

    日本血管外科学会雑誌(Web)　25　(Supplement)　518(J‐STAGE)　2016

    ISSN： 1881-767X

  103. 術後回復促進策における負の側面とその対策 腹部大動脈瘤開腹手術に対するStroke Volume Variationを指標とした適正な周術期輸液管理法

    清水 拓也, 後藤 均, 亀井 尚, 橋本 宗敬, 赤松 大二朗, 土田 憲, 河村 圭一郎, 田島 悠太, 梅津 道久, 宮田 剛

    日本静脈経腸栄養学会雑誌　31　(1)　234-234　2016/01

    Publisher: (株)ジェフコーポレーション

    ISSN： 2189-0161

  104. 当院における急性下肢虚血の検討

    梅津 道久, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太, 大内 憲明

    脈管学　55　(Suppl.)　S174-S175　2015/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

  105. 振り出しと蹴り出しに着目した末梢動脈疾患患者の歩行分析 三次元動作解析を用いた腸骨動脈病変患者における検討

    柿花 隆昭, 伊藤 修, 伊藤 大亮, 関口 雄介, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太, 梅津 道久, 松本 泰治, 石原 哲郎, 上月 正博

    脈管学　55　(Suppl.)　S121-S121　2015/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  106. 間歇性跛行肢に対するトレッドミル歩行負荷と近赤外線分光法を用いた評価法の検討

    河村 圭一郎, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 田島 悠太, 梅津 道久, 大内 憲明

    脈管学　55　(Suppl.)　S143-S143　2015/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

  107. 腹部大動脈瘤の成因とその拡大・破裂リスク因子に関する観察研究

    田島 悠太, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 深山 紀幸, 濱田 庸, 土田 憲, 河村 圭一郎, 梅津 道久, 大内 憲明

    脈管学　55　(Suppl.)　S164-S164　2015/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

    eISSN： 1880-8840

  108. 経皮的ニトログリセリン投与による血管性間歇性跛行の改善

    土田 憲, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 河村 圭一郎, 田島 悠太, 梅津 道久, 大内 憲明

    脈管学　55　(Suppl.)　S208-S208　2015/10

    Publisher: (一社)日本脈管学会

    ISSN： 0387-1126

  109. 破裂性腹部大動脈瘤治療の未来 開腹手術を第一選択とした破裂性腹部大動脈瘤の治療成績

    後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太, 梅津 道久, 大内 憲明

    日本血管外科学会雑誌　24　(3)　323-323　2015/05

    Publisher: (NPO)日本血管外科学会

    ISSN： 0918-6778

  110. 腹部大動脈瘤の成因とその拡大・破裂リスク因子に関する観察研究

    田島悠太, 後藤均, 橋本宗敬, 赤松大二朗, 清水拓也, 深山紀幸, 濱田庸, 土田憲, 河村圭一郎, 梅津道久, 大内憲明

    脈管学(Web)　55　(supplement)　S164(J‐STAGE)　2015

    ISSN： 1880-8840

  111. 感染を繰り返した肝動静脈奇形の一例

    嶋 健太郎, 兒玉 英謙, 乙供 茂, 中村 香織, 梅津 道久, 武山 大輔, 峰村 出, 佐藤 明史, 大原 勝人, 初貝 和明, 市川 宏文, 富永 現, 赤羽 武弘, 高橋 徹, 金田 巌

    日本肝胆膵外科学会・学術集会プログラム・抄録集　26回　597-597　2014/06

    Publisher: (一社)日本肝胆膵外科学会

  112. 食道癌に対する腹臥位胸腔鏡手術の導入とその成績

    市川 宏文, 初貝 和明, 武山 大輔, 大原 勝人, 児玉 英謙, 峰村 出, 佐藤 明史, 瑞慶覧 努, 嶋 健太郎, 梅津 道久, 中村 香織, 金田 巌

    日本内視鏡外科学会雑誌　18　(7)　680-680　2013/11

    Publisher: (一社)日本内視鏡外科学会

    ISSN： 1344-6703

  113. 当科で経験した甲状腺髄様癌の二例

    富岡 泰章, 峰村 出, 梅津 道久, 佐藤 明史, 大原 勝人, 初貝 和明, 市川 宏文, 高橋 徹, 金田 巖

    日本臨床外科学会雑誌　74　(増刊)　1018-1018　2013/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

  114. 急性虫垂炎に対するInterval appendectomyでAppendiceal mucinous neoplasmを認めた一例

    佐藤 洸二, 峰村 出, 大原 勝人, 初貝 和明, 市川 宏文, 兒玉 英謙, 佐藤 明史, 瑞慶覧 努, 武山 大輔, 嶋 健太郎, 梅津 道久, 中村 香織, 金田 巌

    日本臨床外科学会雑誌　74　(増刊)　1044-1044　2013/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

  115. 保存的治療が奏功しなかった十二指腸壁内血腫の一例

    中村 香織, 佐藤 明史, 初貝 和明, 梅津 道久, 金田 巌

    日本腹部救急医学会雑誌　33　(2)　456-456　2013/02

    Publisher: (一社)日本腹部救急医学会

    ISSN： 1340-2242

  116. くも膜下出血術後にSegmental Arterial Mediolysis(SAM)による腹腔内出血を来し、保存的に治療した一例

    荒川 梨津子, 兒玉 英謙, 石井 正, 市川 宏文, 初貝 和明, 大原 勝人, 村田 幸生, 高橋 一臣, 佐藤 明史, 峰村 出, 瑞慶覧 努, 嶋 健太郎, 木村 尚大, 梅津 道久, 金田 巌

    日本臨床外科学会雑誌　73　(増刊)　670-670　2012/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

  117. 長期臥床の高齢者に発症した盲腸捻転症の一例

    梅津 道久, 木村 尚大, 高橋 一臣, 関根 祐樹, 大原 勝人, 初貝 和明, 石井 正, 金田 巌

    日本臨床外科学会雑誌　72　(増刊)　606-606　2011/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

  118. 成人の仙尾部に発生したdermoid cystの一例

    木村 尚大, 梅津 道久, 高橋 一臣, 関根 祐樹, 大原 勝人, 初貝 和明, 石井 正, 金田 巖

    日本臨床外科学会雑誌　72　(増刊)　759-759　2011/10

    Publisher: 日本臨床外科学会

    ISSN： 1345-2843

Show all ︎Show first 5

Presentations 21

  1. 下肢静脈瘤血管内治療の有害事象:重大合併症は本当に多いのか? 下肢静脈瘤に対するシアノアクリレート系接着材による血管内治療の合併症に関する緊急調査 第二弾調査報告

    梅津 道久, 広川 雅之, 手島 英一, 深谷 絵里, 草川 均, 西部 俊哉, 孟 真, 小川 智弘

    静脈学　2024/05

  2. Edoxaban for 12 versus 3 Months in Cancer-associated Isolated Distal Deep Vein Thrombosis According to Distant Metastases: ONCO DVT Study(タイトル和訳中)

    梅津 道久, 山下 侑吾, 村岡 直穂, 西本 裕二, 高田 卓磨, 荻原 義人, 西川 達哉, 池田 長生, 乙井 一典, 末田 大輔, 津端 由佳里, 庄司 正昭, 志鎌 あゆみ, 細井 温, 田辺 康宏, 茶谷 龍己, 塚原 健吾, 中西 直彦, 金 基泰, 池田 聡司, 赤松 大二朗

    日本循環器学会学術集会抄録集　2024/03

  3. 化学療法センターにおける深部静脈血栓症

    梅津 道久, 赤松 大二朗, 芹澤 玄, 鈴木 峻也, 高橋 宏和, 木村 俊作, 清水 港太, 村上 皓彦, 亀井 尚

    脈管学　2023/10

  4. COVID-19感染症関連血栓症の分析 CLOT-COVID studyの総括(1)

    梅津 道久, 山本 尚人, 中田 弘子, 相川 志都, 佐戸川 弘之, 岩田 英理子, 岩井 武尚, 小川 智弘, 小林 隆夫, 孟 真, 山下 侑吾

    日本血管外科学会雑誌　2023

  5. 静脈および動脈血栓症の分析 CLOT-COVID Studyより

    梅津 道久, 山下 侑吾, 谷地 繊, 竹山 誠, 西本 裕二, 辻野 一三, 中村 順一, 山本 尚人, 中田 弘子, 池田 聡司, 相川 志都, 林 浩也, 佐戸川 弘之, 奥野 善教, 岩田 英理子, 荻原 義人, 池田 長生, 近藤 朱音, 岩井 武尚, 山田 典一, 小川 智弘, 小林 隆夫, 孟 真

    静脈学　2022/06

  6. 血栓後症候群の治療経験

    梅津 道久, 赤松 大二朗, 亀井 尚

    静脈学　2021/11

  7. 妊娠関連深部静脈血栓症に対する治療

    梅津 道久, 赤松 大二朗, 芹澤 玄, 田島 悠太, 堀井 晋一良, 小笠原 紀信, 高橋 宏和, 長岡 洋平, 亀井 尚

    脈管学　2021/10

  8. 超常磁性酸化鉄造影剤を用いた核磁気共鳴画像法による腹部大動脈瘤の中膜および外膜内の組織マクロファージの局在評価

    梅津 道久, 後藤 均, 赤松 大二朗, 菅原 宏文, 濱田 庸, 土田 憲, 吉田 良太朗, 鈴木 峻也, 堀井 晋一良, 内藤 剛, 石田 孝宜, 海野 倫明, 亀井 尚

    日本外科学会定期学術集会抄録集　2019/04

  9. 多領域に血栓が充満したVTEに対する血管内治療の役割

    梅津 道久, 後藤 均, 赤松 大二朗, 菅原 宏文, 濱田 庸, 土田 憲, 吉田 良太朗, 鈴木 峻也, 堀井 晋一良, 小笠原 紀信, 海野 倫明, 亀井 尚

    日本血管外科学会雑誌　2019

  10. 担癌患者に対するVTE治療の変遷

    梅津 道久, 後藤 均, 橋本 宗敬, 赤松 大二朗, 菅原 宏文, 土田 憲, 鈴木 峻也, 亀井 尚

    日本血管外科学会雑誌　2018/06

  11. 担癌患者に対するVTE治療の変遷

    梅津道久, 後藤均, 橋本宗敬, 赤松大二朗, 菅原宏文, 土田憲, 鈴木峻也, 亀井尚

    日本血管外科学会雑誌(Web)　2018/06

  12. 担癌患者に対する静脈血栓塞栓症治療の選択

    梅津 道久, 後藤 均, 橋本 宗敬, 赤松 大二朗, 土田 憲, 田島 悠太, 鈴木 峻也

    脈管学　2017/10

  13. 左内胸動脈を流入血管としたCABG後に生じた左鎖骨下動脈狭窄の一例

    梅津道久, 後藤均, 大原勝人, 橋本宗敬, 赤松大二朗, 土田憲, 田島悠太, 鈴木峻也

    日本血管外科学会雑誌(Web)　2017

  14. 腎動脈瘤におけるMPR再構成を用いた瘤径の経時的変化の検討

    梅津 道久, 後藤 均, 大原 勝人, 橋本 宗敬, 赤松 大二朗, 土田 憲, 田島 悠太

    脈管学　2016/10

  15. 当院における急性下肢虚血の検討

    梅津 道久, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太

    日本外科学会定期学術集会抄録集　2016/04

  16. 急性発症し長期加療を要した重症虚血肢の1例

    梅津 道久, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太

    日本下肢救済・足病学会誌　2016/03

  17. 当院で経験した膠原病に合併した重症虚血肢の検討

    梅津道久, 後藤均, 橋本宗敬, 赤松大二朗, 清水拓也, 土田憲, 河村圭一郎, 田島悠太

    日本血管外科学会雑誌(Web)　2016

  18. 当院における急性下肢虚血の検討

    梅津 道久, 後藤 均, 橋本 宗敬, 赤松 大二朗, 清水 拓也, 土田 憲, 河村 圭一郎, 田島 悠太, 大内 憲明

    脈管学　2015/10

  19. 上腸間膜静脈血栓症を伴った腹部炎症性疾患の2例

    梅津 道久, 佐藤 明史, 金田 巌

    日本腹部救急医学会雑誌　2013/02

  20. 外傷性膵十二指腸損傷に対して緊急膵頭十二指腸切除を施行した一例

    梅津 道久, 中村 香織, 小林 道生, 大原 勝人

    日本腹部救急医学会雑誌　2012/02

  21. 長期臥床の高齢者に発症した盲腸捻転症の一例

    梅津 道久, 木村 尚大, 高橋 一臣, 関根 祐樹, 大原 勝人, 初貝 和明, 石井 正, 金田 巌

    日本臨床外科学会雑誌　2011/10

Show all Show first 5

Research Projects 6

  1. Establishment of human abdominal aortic aneurysm wall strength prediction model using Ex Vivo Superparamagnetic Iron Oxide&#8211;Enhanced Magnetic Resonance Imaging

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research

    Category: Grant-in-Aid for Scientific Research (C)

    Institution: Tohoku University

    2023/04/01 - 2028/03/31

  2. 次世代放射光と質量分析イメージングで明らかにする腹部大動脈壁構造と瘤径拡大の関連

    梅津 道久

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 東北大学

    2024/04/01 - 2027/03/31

  3. 次世代シーケンサーで明らかにする動脈硬化症と細菌との関連

    吉田 良太朗, 濱中 洋平, 赤松 大二朗, 原田 成美, 梅津 道久, 田島 悠太

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 東北大学

    2021/04/01 - 2024/03/31

    More details Close

    本研究の目的は動脈硬化症の進展において重要な要因となっている‘炎症反応’に細菌が如何に関与しているかを明らかにする事を目的としている。‘動脈病変局所における不顕性感染’または‘特徴的な腸内細菌叢’が産生する特異的な代謝産物等が遠隔的に働いて炎症の原因として関与しているものと推察している。人種間で腸内細菌叢が異なることが知られており、日本人における腸内細菌叢と動脈硬化との関連を明らかにすることは大きな意義がある。また本研究では病巣局所における感染が関わっているのかを明らかにするため組織における細菌をメタゲノム解析で検出して組織の炎症像との関連を明らかにするが、組織標本から同手法により細菌検出を試みた報告は世界でも類が無い。またメタトランスクリプトーム解析・メタボローム解析を用いて得られた細菌代謝産物と動脈硬化組織の炎症像との関係をヒトにおいて明らかにした報告はない。具体的には以下の研究を実行する。①下肢閉塞性動脈硬化症患者(lower extremity atherosclerosis: LEA)の動脈病変組織と糞便中の細菌をメタゲノム解析で同定し、動脈硬化巣と糞便中の最近の一致を検討する。局所における細菌の有無と動脈硬化組織における炎症との関連を検討する。②LEA患者の糞便からメタトランスクリプトーム解析を用いて細菌が発現する遺伝子と代謝系を明らかにする。併せて血液のメタボローム解析を行い、細菌発現遺伝子・代謝産物と動脈硬化組織の炎症との関連を検討する。③LEA患者と健常者の糞便をメタゲノム解析・メタボローム解析し比較する。④LEA患者と健常者の血液をメタボローム解析し比較する。⑤動脈組織のメタトランスクリプトーム解析・メタボローム解析を行い、局所の炎症像との関連を検討する。糞便中のメタトランスクリプトーム解析・メタボローム解析結果との比較検討を行う。

  4. Helicobacter cinaediの除菌による腹部大動脈瘤伸展抑制の検討

    後藤 均, 吉田 良太朗, 田島 悠太, 赤松 大二朗, 梅津 道久

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 東北大学

    2021/04/01 - 2024/03/31

    More details Close

    腹部大動脈瘤(AAA)の治療は現在のところ外科的治療のみが確立されている。AAAの成因はまだ不明な点が多く、薬剤でAAAを抑制する試みはまだ成功していない。AAA発症の一因として以前から微生物の感染による炎症がトリガーになる可能性が報告されていたが、その原因となる微生物は同定されないままでいた。一方、近年、動脈硬化巣からHelicobacter cinaediが同定されるようになり新たな生活習慣病を起こす常在菌として注目されている。H.cinaediは培養による検出が難しくnested PCRでの検出系が確立されたのは最近のことである。H.cinaediはヒトに不顕性感染を起こし、動脈硬化の発症プロセスに関与する報告があることから、我々はH.cinaediがAAA発症のトリガーになっていないだろうかと考え、手術標本の瘤壁に対してnested PCR法によりH.cinaediの存在を評価した。その結果39例中23％にH.cinaediのDNAが検出され、また同個体の正常動脈からはH.cinaedi遺伝子が検出されないことから、H.cinaediは瘤形成に何らかの関わりがあるものと考えている。 そこで、本研究では以下のステップを経てAAAの薬剤による抑制ができるかを確認する。① AAA症例の血清を用いH.cinaedi抗体価の測定を行う。②小瘤径AAAのH.cinaedi陽性例を2群にわけ、片方には抗生剤の1週間投与により「除菌」を行う。もう一方はコントロールとする。③除菌群とコントロール群のAAAの拡大の経過を最低3年間追跡し「除菌」によりAAAの拡 大が抑制できるかどうかを検討する。AAAの発症には複雑な要因が関連すると考えられるが以上の方法が確立されれば一部の AAAに対しては薬剤によりその拡大を抑制するという新しい治療選択になる可能性がある。

  5. 腹部・腸骨動脈瘤における内腸骨動脈再建の適応と臀筋跛行リハビリテーション法の提示

    赤松 大二朗, 後藤 均, 柿花 隆昭, 梅津 道久, 菅原 宏文, 田島 悠太, 土田 憲, 関口 雄介

    Offer Organization: 日本学術振興会

    System: 科学研究費助成事業

    Category: 基盤研究(C)

    Institution: 東北大学

    2020/04/01 - 2023/03/31

    More details Close

    2016年に内腸骨動脈再建用のステントグラフトが保険収載されて以来、EVAR（ステントグラフト内挿術）とOS（開腹人工血管置換術）何れの術式でも内腸骨動脈再建は可能となったが再建の適応は術者の裁量に任されているのが現状である。内腸骨動脈塞栓による臀筋跛行ならびに臀筋循環の予後を明らかにし、歩行障害を長期化させる要因を明らかにすることで内腸骨動脈再建の適応を提示する事が本研究の第一の目的である。これにより不要な再建を避け、合併症と医療費の軽減に繋がることが期待出来る。また内腸骨動脈末梢側が瘤化している際には内腸骨動脈塞栓は不可避となる。内腸骨動脈塞栓による歩容への影響を三次元動作解析装置で明らかにする事によって適切なリハビリテーションを考案し、歩行機能の維持と転倒予防に繋げる事が本研究の第二の目的である。本研究により、手術治療で破裂予防が得られてもQOLやADLが低下し日常生活に支障を来した患者にとって大きな福音となると考えられる。また本手法を用いることで三次元動作解析からの他の疾患特異的リハビリプログラムにも応用できると考えられ、社会的貢献も非常に大きいと考えられる。 具体的には東北大学病院総合外科でOSおよびEVAR手術適応となった腹部大動脈―腸骨動脈瘤患者の内、片側もしくは両側の内腸骨動脈塞栓を要する患者を対象とし、WIQ score(Walking Impairment Questionaire)を用いた主観的跛行症状の評価と６分間歩行検査、三次元動作解析装置(Motion analysis社製)を用いた解析を実施した。COVID-19蔓延による影響のため、実施数は少数例であったが、今後は感染動向および院内の方針を踏まえて実施数を増やしたい。

  6. Useful Imaging to detect Macrophage Localization in the Media and Adventitia of the Abdominal Aortic Aneurysm Wall using Ex Vivo Superparamagnetic Iron Oxide-Enhanced Magnetic Resonance Imaging

    Shimizu Takuya, UMETSU Michihisa

    Offer Organization: Japan Society for the Promotion of Science

    System: Grants-in-Aid for Scientific Research

    Category: Grant-in-Aid for Scientific Research (C)

    Institution: Tohoku University

    2015/04/01 - 2019/03/31

    More details Close

    Macrophages in the aneurysmal wall play an important role in the pathogenesis of abdominal aortic aneurysms (AAAs). superparamagnetic iron oxide (SPIO) is a macrophage-specific contrast agent that result in negative enhancement on T2*-weighted imaging. We attempted to evaluate macrophage localization in the media and adventitia of AAA wall using SPIO-enhanced MRI. Ex vivo MRI was performed for the specimens in SPIO group. There was significant positive correlation between berlin blue-stained macrophages and berlin blue positive area in SPIO group with macrophages. We divided the media and adventitia in each specimen and compared the ROI of T2*-weighted SPIO-enhanced MRI with berlin blue-stained area. We found significant correlations in 5 of 7 cases with macrophages. We detected that ex vivo T2*-weighted SPIO-enhanced MR findings visualize a macrophage localization in the media and adventitia. This imaging technique would also visualize the macrophage distribution in in-vivo MRI.

Show all Show first 5

Teaching Experience 1

  1. 腫瘍関連学際領域特論 腫瘍循環器学4　東北広域次世代がんプロ養成プラン

Social Activities 3

  1. 授業講演「血管外科医」

    2020/09/07 - 2020/09/07

  2. 授業講演「自分の生き方を考えよう」

    開北小学校

    2013/02/08 - 2013/02/08

  3. 授業講演「夢を語る会」

    2011/12/10 - 2011/12/10

Media Coverage 5

  1. Large survey in Japan finds cyanoacrylate closure for varicose veins “safe” with low adverse event rate

    Venous news

    2025/02

    Type: Internet

  2. ＜更生現場のいま＞心身の弱さ克服 第一歩に

    河北新報　河北新報

    2019/03/18

    Type: Newspaper, magazine

  3. 震災時 石巻に残った29歳外科医

    日刊スポーツ　日刊スポーツ

    2013/11/04

    Type: Newspaper, magazine

  4. Review of Activities 2013 Voice from Japan Myself

    2013/10

    Type: Promotional material

  5. 上山出身の梅津医師、救命の務め懸命に

    山形新聞　山形新聞

    2011/03/28

    Type: Newspaper, magazine